var title_f21_40_22144="Patient information: The ABCs of diabetes (The Basics)";
var content_f21_40_22144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: The ABCs of diabetes (The Basics)",
"  </div>",
"  <a href=\"./authors-and-editors/patient-information\">",
"   Written by the doctors and editors at UpToDate",
"  </a>",
"  <br/>",
"  <br/>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 4, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1730387707\">",
"    <span class=\"h1\">",
"     What can I do to stay as healthy as possible if I have diabetes?",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you have diabetes (sometimes called diabetes mellitus), the most important thing you can do is to control your &ldquo;ABCs&rdquo;:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       &ldquo;A&rdquo; stands for &ldquo;A1C&rdquo;",
"      </strong>",
"      &ndash; A1C is a blood test that shows what your average blood sugar level has been during the last few months.",
"     </li>",
"     <li>",
"      <strong>",
"       &ldquo;B&rdquo; stands for &ldquo;blood pressure&rdquo;",
"      </strong>",
"      &ndash; If you have diabetes, controlling your blood pressure is just as important as controlling your blood sugar. High blood pressure puts you at risk for heart attack, stroke, and kidney disease.",
"     </li>",
"     <li>",
"      <strong>",
"       &ldquo;C&rdquo; stands for &ldquo;cholesterol&rdquo;",
"      </strong>",
"      &ndash; Cholesterol is a waxy substance found in the blood. High cholesterol is another factor that increases your risk of heart attacks, strokes, and other serious problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730387714\">",
"    <span class=\"h1\">",
"     Why are my ABCs so important?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with people who do not have diabetes, people who have diabetes are 2 to 3 times more likely to have a heart attack or a stroke. People with diabetes also have heart attacks at a younger age, and that are more severe and more deadly. Plus, people with diabetes are much more likely to get kidney disease. By keeping your ABCs under control, you can lower your risk of these problems by a lot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730387721\">",
"    <span class=\"h1\">",
"     Isn&rsquo;t my blood sugar the most important thing?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keeping blood sugar low is important in preventing some problems caused by diabetes, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eye diseases that lead to vision loss or blindness",
"     </li>",
"     <li>",
"      Kidney disease",
"     </li>",
"     <li>",
"      Nerve damage (called &ldquo;neuropathy&rdquo;) that can cause numbness or pain in the hands and feet",
"     </li>",
"     <li>",
"      The need to have toes, fingers, or other body parts removed by surgery (amputated)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even so, blood sugar is just one of the things that should get your attention. That&rsquo;s because the problems caused by high blood pressure and high cholesterol are often more serious than the ones caused by high blood sugar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730387728\">",
"    <span class=\"h1\">",
"     What should my ABC levels be?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The levels you should aim for will depend on how severe your diabetes is, how old you are, and what other health problems you have. Ask your doctor or nurse what your target levels should be.",
"   </p>",
"   <p>",
"    Many people with diabetes aim for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A1C levels below 7 percent",
"     </li>",
"     <li>",
"      Blood pressure below",
"      <span class=\"nowrap\">",
"       140/90,",
"      </span>",
"      or lower in some cases",
"     </li>",
"     <li>",
"      LDL cholesterol level below 100 (LDL is one type of cholesterol, often called the &ldquo;bad cholesterol&rdquo; or &ldquo;lousy cholesterol&rdquo;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730387735\">",
"    <span class=\"h1\">",
"     How can I control my ABCs?",
"    </span>",
"    &nbsp;&mdash;&nbsp;You and your doctor will work together to create a plan to keep your ABCs under control. Your plan might include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medicines",
"      </strong>",
"      &ndash; Most people with diabetes take medicine every day to control their blood sugar. They might also need to check their blood sugar level every day. Plus, many people with diabetes need medicines every day to treat high blood pressure or high cholesterol, or to prevent future health problems. If you have any problems with your medicines, or you cannot afford them, talk to your doctor or nurse about these issues.",
"     </li>",
"     <li>",
"      <strong>",
"       Lifestyle changes",
"      </strong>",
"      &ndash; Choices you make every day about the foods you eat and the way you live can have a big impact on your ABCs and your general health. Here are some things you can do to help keep your ABCs under control or reduce your health risks:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Make healthy food choices &ndash; Eat lots of fruits, vegetables, whole grains, and low-fat dairy products. Limit the amount of meat and fried or fatty foods that you eat.",
"     </li>",
"     <li>",
"      Be active &ndash; Walk, garden, or do something active for 30 minutes or more on most days of the week.",
"     </li>",
"     <li>",
"      Stop smoking &ndash; Smoking increases the chance that you will have a heart attack or stroke, or develop cancer.",
"     </li>",
"     <li>",
"      Lose weight &ndash; Being overweight increases the risk of many health problems.",
"     </li>",
"     <li>",
"      Avoid alcohol &ndash; Alcohol can increase blood sugar and blood pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Luckily, many of the lifestyle changes above can improve all 3 of the ABCs. For instance, being active and losing weight can help control blood sugar, blood pressure, and cholesterol levels (",
"    <a class=\"graphic graphic_table graphicRef82356 \" href=\"UTD.htm?23/9/23708\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730387742\">",
"    <span class=\"h1\">",
"     More on this topic",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"     Patient information: Type 1 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"     Patient information: Type 2 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"     Patient information: Diabetes and diet (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"     Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"     Patient information: Nerve damage caused by diabetes (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"     Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"     Patient information: High blood pressure in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"     Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"     Patient information: Diabetic neuropathy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"     Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"     Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15751 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4A615F36C0-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22144=[""].join("\n");
var outline_f21_40_22144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1730387707\">",
"      What can I do to stay as healthy as possible if I have diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1730387714\">",
"      Why are my ABCs so important?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1730387721\">",
"      Isn&rsquo;t my blood sugar the most important thing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1730387728\">",
"      What should my ABC levels be?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1730387735\">",
"      How can I control my ABCs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1730387742\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   GRAPHICS",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     TABLES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/9/23708\" title=\"table 1\">",
"      Ways to get your ABCs under control PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=related_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=related_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=related_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=related_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22145="Histology lung 1C answer";
var content_f21_40_22145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histoplasmosis in the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin-stained section of splenic tissue (x1000) obtained from a patient with overwhelming histoplasmosis, who presented with pneumonia. A macrophage in the center of the slide contains many yeast forms of Histoplasma capsulatum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22145=[""].join("\n");
var outline_f21_40_22145=null;
var title_f21_40_22146="Patient information: Lead poisoning (The Basics)";
var content_f21_40_22146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16244\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?29/3/29755\">",
"         Ways to prevent exposure to lead in paint",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?3/30/3563\">",
"          Ways to prevent exposure to lead in soil",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?43/12/44235\">",
"           Ways to reduce the amount of lead your family takes in",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?6/42/6828\">",
"            Ways to clean to decrease exposure to lead in dust",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lead poisoning (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lead-poisoning-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6108126\">",
"      <span class=\"h1\">",
"       What is lead poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lead poisoning is a serious medical problem that mostly affects children. It happens when too much lead gets into a person&rsquo;s body.",
"     </p>",
"     <p>",
"      Lead poisoning can damage the brain, kidneys, and other organs. In children, lead poisoning can cause learning and memory problems that can never be fixed.",
"     </p>",
"     <p>",
"      Lead is a metal, so people think of it as something that you find only in pipes or other metal objects. The truth is, lead can be found in all kinds of things, including dust, wall paint, old toys or toys that came from outside the US, pottery, soil, and even drinking water.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6108133\">",
"      <span class=\"h1\">",
"       How can a person get lead poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on whether the person is a child or an adult.",
"     </p>",
"     <p>",
"      A child can get lead poisoning in a few different ways:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The child can swallow or inhale lead in dust. House paint used to be made with lead in it. Many old houses still have that paint. As the paint slowly chips or peels, lead can get into dust. Young children often end up eating that dust, because they get it on their hands and then put their hands in their mouth. Children can also get very sick if they eat peeling paint that has lead in it. Children who live in homes built before 1978 are at especially high risk of getting lead poisoning this way.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The child can swallow lead in water or food. The pipes in some homes have lead in them, so lead can get into water that way. Foods can get lead in them if they are stored in certain types of cans or if they have certain spices. Foods made in countries besides the US are more likely to have lead in them than those made in the US.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The child can chew or suck on toys, jewelry, or other products that have lead in them. This does not happen often, but toys imported from countries besides the US sometimes have lead in them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In adults, lead poisoning is less common than it is in children. That&rsquo;s because the body develops a natural way to protect itself from lead as it gets older. Even so, adults can get lead poisoning if they have a job or a hobby that involves using materials that have lead. For example, adults can get lead poisoning if they:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Work with lead paint (painting bridges or boats, for example)",
"       </li>",
"       <li>",
"        Are exposed to lead fumes (because they work in battery recycling or in a plant that processes lead, for example)",
"       </li>",
"       <li>",
"        Make ceramics or stained glass",
"       </li>",
"       <li>",
"        Remodel their home and there is lead in the paint that was used when the home was built",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6108140\">",
"      <span class=\"h1\">",
"       What are the symptoms of lead poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most young children with lead poisoning have no symptoms. That is why it&rsquo;s so important to screen children at risk for lead poisoning (such as those living in houses built before 1978). When symptoms occur, they vary depending on how much lead a person is exposed to.",
"     </p>",
"     <p>",
"      In general, a child with symptoms might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel tired",
"       </li>",
"       <li>",
"        Have a stomach ache",
"       </li>",
"       <li>",
"        Feel constipated",
"       </li>",
"       <li>",
"        Feel irritable",
"       </li>",
"       <li>",
"        Vomit",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6108147\">",
"      <span class=\"h1\">",
"       Is there a test for lead poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are blood tests that measure the amount of lead in a person&rsquo;s body. Different states have different rules about who should be checked for lead and when. You should ask your child&rsquo;s doctor if your child needs to be screened for lead poisoning.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6108154\">",
"      <span class=\"h1\">",
"       How is lead poisoning treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important &ldquo;treatment&rdquo; for lead poisoning is to get rid of the source of the lead. For example, if a child got lead poisoning from paint dust in his or her home, then a professional should remove all the lead paint (called &ldquo;lead abatement&rdquo;) from the child&rsquo;s home. If that is not possible, the child should move to a new home that is lead-free. Both options are complicated and expensive. But the only way to fully protect a child is to remove the source of lead from his or her surroundings.",
"     </p>",
"     <p>",
"      If the child lives in a rented home, the person who owns the home might be responsible for removing the lead.",
"     </p>",
"     <p>",
"      For people with very high levels of lead, doctors sometimes suggest a treatment called &ldquo;chelation&rdquo; therapy. This involves taking a medicine that helps pull lead out of the body. The medicine can come in pills or in a shot. But doctors can give this medicine only if they are sure that the person is no longer being exposed to lead. If the person is still being exposed to lead, the medicine can actually make lead poisoning worse. Plus, chelation does not prevent or undo the long-term effects of lead on learning and intelligence.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6108161\">",
"      <span class=\"h1\">",
"       Can lead poisoning be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The most important thing you can do to prevent lead poisoning is to avoid exposure to lead in paint (",
"      <a class=\"graphic graphic_table graphicRef66646 \" href=\"UTD.htm?29/3/29755\">",
"       table 1",
"      </a>",
"      ), soil (",
"      <a class=\"graphic graphic_table graphicRef61589 \" href=\"UTD.htm?3/30/3563\">",
"       table 2",
"      </a>",
"      ), and other sources (",
"      <a class=\"graphic graphic_table graphicRef79574 \" href=\"UTD.htm?43/12/44235\">",
"       table 3",
"      </a>",
"      ). If you know there is lead in your home, it&rsquo;s also important to clean your house the right way (",
"      <a class=\"graphic graphic_table graphicRef78821 \" href=\"UTD.htm?6/42/6828\">",
"       table 4",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If you decide to have lead removed from your home, make sure to hire a contractor who is &ldquo;certified in lead abatement.&rdquo; These are contractors who are certified know how to remove lead safely. They also know how to protect your family and the things inside your home while the work is being done.",
"     </p>",
"     <p>",
"      Another way to prevent or reduce the effects of lead poisoning is to eat a diet rich in calcium, vitamin D, vitamin C, and iron. Good food choices include milk, yogurt, fortified cereals, fish, lean meats, oranges, and tomatoes. Plus, children should get a multivitamin with iron every day. (Check with your pharmacist about which multivitamin is right for your child.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6108168\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant and have been told you have lead levels that are too high, you might need treatment. Make sure that your baby&rsquo;s doctor knows the levels of lead in your body. Even tiny amounts of lead can cause serious problems for a baby.",
"     </p>",
"     <p>",
"      If you have lead poisoning, the blood from your baby&rsquo;s umbilical cord should be tested at birth, or your baby should have a lead test within 2 weeks of being born.",
"     </p>",
"     <p>",
"      If you have lead poisoning, do not breastfeed unless your doctor tells you it is safe. If you are able to breastfeed, you and your baby will need blood tests to make sure that your baby&rsquo;s lead level does not get any higher.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/40/22146?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16244 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22146=[""].join("\n");
var outline_f21_40_22146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108126\">",
"      What is lead poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108133\">",
"      How can a person get lead poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108140\">",
"      What are the symptoms of lead poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108147\">",
"      Is there a test for lead poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108154\">",
"      How is lead poisoning treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108161\">",
"      Can lead poisoning be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6108168\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/3/29755\">",
"      Ways to prevent exposure to lead in paint",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?3/30/3563\">",
"       Ways to prevent exposure to lead in soil",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"UTD.htm?43/12/44235\">",
"        Ways to reduce the amount of lead your family takes in",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?6/42/6828\">",
"         Ways to clean to decrease exposure to lead in dust",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22147="Vaginoscopy";
var content_f21_40_22147=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaginoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22147/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22147/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22147/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22147/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22147/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22147/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/40/22147/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginoscopy refers to use of an instrument, other than a speculum, to visualize the vaginal canal. It is used most often for examination of children. The clinician should choose an instrument that will not damage the hymen or lower genital tract of the unestrogenized child. The anatomic integrity of the child's hymenal tissue is important from a cultural and forensic point of view: families often need to be assured the child will remain virginal; anatomic disruptions of the hymenal tissues are used as forensic evidence of childhood sexual abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREPROCEDURE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to insertion of any instrument into the vaginal introitus, the anatomic features of the hymen should be documented and the amount of estrogen effect on the child's tissues should be assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link&amp;anchor=H7#H7\">",
"     \"The pediatric physical examination: The perineum\", section on 'Females'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link&amp;anchor=H3#H3\">",
"     \"Gynecologic examination of the newborn and child\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hymenal tissue with a high estrogen effect (newborns and peripubertal children) is better able to tolerate iatrogenic stretch without tearing than tissue with a very low estrogen effect (children three to eight years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/1\">",
"     1",
"    </a>",
"    ]. A pediatric vaginal speculum should not be used in routine examination of the prepubertal child's vagina because there is a risk of traumatizing the hymen and vaginal walls, even if the child is under general anesthesia.",
"   </p>",
"   <p>",
"    Vaginoscopy with an irrigating endoscope can be performed in the office or as an examination under anesthesia (see below). The site is determined by the child's ability to comply with instructions. Topical anesthetic is applied to the vulva approximately five minutes before inserting the vaginoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/1\">",
"     1",
"    </a>",
"    ]; the author uses a 2 percent preparation of viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . The author is more comfortable using a flexible irrigating endoscope for office procedures due to concern about inadvertent patient movement that might result in accidental injury. Patient compliance can be improved when the child is informed that she will be able to see what the doctor sees inside her body. A flexible scope can be bent toward the patient so she can visualize her lower genital tract or a video attachment with a monitor can be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSTRUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, a popular technique for examination of a child's vagina involved the Cameron-Myers vaginoscope, which has interchangeable distal tubular structures of 0.7, 1.0, and 1.3 cm diameters (",
"    <a class=\"graphic graphic_picture graphicRef52829 \" href=\"UTD.htm?42/0/43010\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This instrument was a modification of a veterinary otoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The Killian nasal speculum has also been used for pediatric vaginoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/6\">",
"     6",
"    </a>",
"    ]. Use of these instruments allows detection of large lesions and those that are a different color than the vaginal walls. However, if the lesion is accompanied by copious mucus or debris or is very small, detecting it with these instruments is difficult.",
"   </p>",
"   <p>",
"    Vaginoscopy with an irrigating endoscope is ideal for examination of the lower reproductive tract of a prepubertal female (",
"    <a class=\"graphic graphic_figure graphicRef79212 \" href=\"UTD.htm?38/8/39041\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The small diameter of the endoscope causes no distortion of the hymenal tissues and the irrigation fluid will not only lavage the vagina, but distend it sufficiently to allow good visualization of the cervix and vaginal canal. Lavaging the vagina of mucus and debris is important for detection of extremely small exophytic lesions that can be camouflaged. In addition, a small exophytic lesion will flap freely in the irrigating fluid, aiding in its detection.",
"   </p>",
"   <p>",
"    Distension of the vaginal canal by fluid allows the cervix and the vagina to be visualized together. Use of an instrument other than an irrigating vaginoscope will not allow this panoramic view, since the Cameron-Myers vaginoscope or veterinary otoscope will only visualize what is directly adjacent to the distal portal of the scope. The general panoramic view of the cervix and vagina helps the examiner to appreciate any anatomic asymmetries suggestive of congenital anomalies, such as ectopic ureters (",
"    <a class=\"graphic graphic_picture graphicRef56967 \" href=\"UTD.htm?25/55/26480\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58538 \" href=\"UTD.htm?21/54/22369\">",
"     image 1",
"    </a>",
"    ) and m&uuml;llerian defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any endoscope with irrigating properties can be used. A bronchoscope or urethroscope is ideal because of the short length; however, a laparoscope, cystoscope, nephroscope, or hysteroscope can also be used (",
"    <a class=\"graphic graphic_picture graphicRef51231 \" href=\"UTD.htm?5/63/6129\">",
"     picture 3",
"    </a>",
"    ). Hysteroscopes, which have very small diameters, are necessary in some children. This can be a problem because the amount of fluid pressure distending the vaginal canal is lower as the scope diameter becomes smaller. An assistant placing pressure on the irrigating fluid bag or supplementing the pressure of the fluid with an attached large-volume syringe of fluid usually can overcome this problem. Bladder irrigating fluid or normal saline can be used as the distending fluid. High molecular weight fluids, as used in hysteroscopy, offer no advantage and are a deterrent to getting a good seal of the vulvar tissues around the endoscope due to their slippery consistency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the fragility of the prepubertal vaginal epithelium, one will invariably notice pink discoloration on the final swab(s) of a series of swabs used to obtain cultures from the unestrogenized prepubertal vagina. On vaginoscopy, small petechiae will be noted on the cervix or vaginal side walls. This occurs so frequently that it should be considered normal in this situation (",
"    <a class=\"graphic graphic_figure graphicRef64589 \" href=\"UTD.htm?17/11/17588\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rugation of the vaginal walls is variable, but usually low to minimal. Much of the prepubertal side walls are smooth and free of rugae.",
"   </p>",
"   <p>",
"    Extensive papillary projections can be observed around embedded foreign objects. Lesser papillary projections are observed at the site of nonembedded foreign objects. It seems very likely that a foreign object could be expelled with Valsalva's maneuver before its discovery by vaginoscopy. Therefore, the physician should look for sites of papillary excrescences as possible evidence of a recently expelled foreign object when performing vaginoscopy for unexplained vaginal bleeding or discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The unestrogenized vaginal walls will also frequently respond to trauma by forming granulation tissue. The mounds of friable tissue look bizarre under the magnification of vaginoscopy. This granulation tissue will resolve in most cases after application of topical estrogen cream to the vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22147/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If an irrigating vaginoscope is not used, linear lacerations noted with a pediatric speculum would have to be attributed to the trauma of the speculum examination itself. This is detrimental if the examination is being performed to document sexual abuse. Therefore, speculums should never be used for evaluation of genital symptoms in a prepubertal female since abuse is always in the differential. By comparison, the vagina is lavaged during vaginoscopy, thus allowing good definition of acute trauma. However, there will be no vaginal distension if there has been avulsion of the vaginal apex, since the fluid will flow into the abdominal cavity.",
"   </p>",
"   <p>",
"    In most cases without distinct pathology, the vaginoscopy will encounter a smooth or nodular symmetric cervix and smooth or slightly rugated symmetric vaginal canal. Suspicion of a urogenital anomaly must be raised when asymmetry of the cervix or vagina are noted or there are extra craters, dimples, or folds of tissue in the upper vagina.",
"   </p>",
"   <p>",
"    Vaginoscopy with an irrigating endoscope has led to such a superior panoramic view of the prepubertal vagina and cervix that future clinical studies are warranted to better define and outline management for cervical and vaginal variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginoscopy refers to use of an instrument, other than a speculum, to visualize the vaginal canal. It is used most often for examination of children. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginoscopy with an irrigating endoscope is recommended for examination of children (",
"      <a class=\"graphic graphic_figure graphicRef79212 \" href=\"UTD.htm?38/8/39041\">",
"       figure 1",
"      </a>",
"      ). The small diameter of the endoscope causes no distortion of the hymenal tissues and the irrigation fluid will not only lavage the vagina, but distend it sufficiently to allow good visualization of the cervix and vaginal canal.",
"     </li>",
"     <li>",
"      Extensive papillary projections can be observed around embedded foreign objects. A urogenital anomaly should be suspected when asymmetry of the cervix or vagina are noted or there are extra craters, dimples, or folds of tissue in the upper vagina. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22147/abstract/1\">",
"      Yordan EE, Yordan RA. The hymen and tanner staging of the breast. Adolesc Pediatr Gynecol 1992; 5:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22147/abstract/2\">",
"      Capraro VJ. Gynecologic examination in children and adolescents. Pediatr Clin North Am 1972; 19:511.",
"     </a>",
"    </li>",
"    <li>",
"     Droegemueller W. Pediatric gynecology. In: Comprehensive Gynecology, Droegemueller W, Herbst AL, Mishell DR Jr, Stenchever MA (Eds), CV Mosby, St. Louis 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22147/abstract/4\">",
"      Billmire ME, Farrell MK, Dine MS. A simplified procedure for pediatric vaginal examination: use of veterinary otoscope specula. Pediatrics 1980; 65:823.",
"     </a>",
"    </li>",
"    <li>",
"     Brenner PF. Infancy and childhood. In: Gynecology and Obstetrics: The Health Care of Women, Romney SL, Gray MJ, Little AB et al (Eds), McGraw-Hill, New York 1981.",
"    </li>",
"    <li>",
"     Laufer MR. Gynecologic Pain: Dysmenorrhea, Acute and Chronic Pelvic Pain, Endometriosis, and Premenstrual Syndrome. In: Pediatric &amp; Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Wolters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.238.",
"    </li>",
"    <li>",
"     Pokorny SF. The genital examination of the infant through adolescence. In: Current Opinion in Obstetrics and Gynecology, Goldfarb AA (Ed), Current Science, 1993. p.753.",
"    </li>",
"    <li>",
"     Pokorny SF. Pediatric gynecology. In: Office Gynecology, Stenchever MA (Ed), Mosby-Year, St. Louis 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22147/abstract/9\">",
"      Bacsk&oacute; G. [Use of the hysteroscope in pediatric gynecology for diagnosis of vaginal hemorrhage and injury]. Zentralbl Gynakol 1993; 115:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22147/abstract/10\">",
"      Pokorny SF. Long-term intravaginal presence of foreign bodies in children. A preliminary study. J Reprod Med 1994; 39:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22147/abstract/11\">",
"      Pokorny SF, Pokorny WJ, Kramer W. Acute genital injury in the prepubertal girl. Am J Obstet Gynecol 1992; 166:1461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3257 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22147=[""].join("\n");
var outline_f21_40_22147=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREPROCEDURE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSTRUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3257|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/54/22369\" title=\"diagnostic image 1\">",
"      Radiograph of ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3257|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/8/39041\" title=\"figure 1\">",
"      Vaginoscopy of a child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/11/17588\" title=\"figure 2\">",
"      Vaginscopy findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3257|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/0/43010\" title=\"picture 1\">",
"      Vaginoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/55/26480\" title=\"picture 2\">",
"      Ectopic ureter thru vaginoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/63/6129\" title=\"picture 3\">",
"      Nephroscope",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22148="Guaifenesin and pseudoephedrine: Drug information";
var content_f21_40_22148=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/60/6085?source=see_link\">",
"    see \"Guaifenesin and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambifed-G [OTC];",
"     </li>",
"     <li>",
"      Congestac&reg; [OTC];",
"     </li>",
"     <li>",
"      ExeFen-IR;",
"     </li>",
"     <li>",
"      Maxifed [OTC];",
"     </li>",
"     <li>",
"      Maxifed-G [OTC] [DSC];",
"     </li>",
"     <li>",
"      Mucinex&reg; D Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; D [OTC];",
"     </li>",
"     <li>",
"      Refenesen Plus [OTC];",
"     </li>",
"     <li>",
"      SudaTex-G [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Contac&reg; Cold-Chest Congestion, Non Drowsy, Regular Strength;",
"     </li>",
"     <li>",
"      Entex&reg; LA;",
"     </li>",
"     <li>",
"      Novahistex&reg; Expectorant with Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Expectorant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Expectorant/decongestant:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ambifed-G, Mucinex&reg; D Maximum Strength: One tablet every 12 hours (maximum: 2 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Congestac&reg;: One caplet every 4-6 hours (maximum: 4 caplets in 24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maxifed-G&reg;, Mucinex&reg; D: 1-2 tablets every 12 hours (maximum: 4 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maxifed&reg;: One to 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablets every 12 hours (maximum: 3 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Expectorant/decongestant:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children 2-6 years",
"     </i>",
"     (Maxifed-G&reg;): One-third to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet every 12 hours (maximum: 1 tablet/12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children 6-12 years:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambifed-G, Maxifed&reg;: One-half caplet or tablet every 12 hours (maximum: 1 tablet/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Congestac&reg;: One-half caplet every 4-6 hours (maximum: 2 caplets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxifed-G&reg;: One-half to 1 tablet every 12 hours (maximum: 2 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Congestac&reg;, Refenesen Plus: Guaifenesin 400 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambifed-G: Guaifenesin 400 mg and pseudoephedrine hydrochloride 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ExeFen-IR: Guaifenesin 400 mg and pseudoephedrine hydrochloride 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxifed: Guaifenesin 400 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxifed-G [DSC], SudaTex-G: Guaifenesin 400 mg and pseudoephedrine hydrochloride 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; D: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; D Maximum Strength: Guaifenesin 1200 mg and pseudoephedrine hydrochloride 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Long acting formulations should not be crushed or chewed. May interfere with sleep; administering some products a few hours before bedtime may help minimize insomnia. Take with full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of nasal congestion and to help loosen phlegm and thin bronchial secretions in the treatment of cough",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F177886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Entex&reg; may be confused with Tenex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Entex&reg; LA brand name represents a different product in the U.S. than it does in Canada. In the U.S., Entex&reg;  LA contains guaifenesin and phenylephrine, while in Canada the product bearing this brand name contains guaifenesin and pseudoephedrine.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin, pseudoephedrine, sympathomimetic amines, or any component of the formulation; use with or within 14 days of MAO inhibitor; severe hypertension or cardiovascular disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F177860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Respaire-30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-150 mg (100): $59.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Mardrops-EX Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-50 mg/mL (30 mL): $6.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Mucinex D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-600 mg (18): $11.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120-1200 mg (24): $23.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aldex GS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-190 mg (100): $121.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Congestac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-400 mg (12): $4.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Entex T Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-375 mg (30): $29.25",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actifed Chesty Syrup (NZ);",
"     </li>",
"     <li>",
"      Contac Cold-Chest Congestion, Non Drowsy, Regular Strength (CA);",
"     </li>",
"     <li>",
"      Entex LA (CA);",
"     </li>",
"     <li>",
"      Guaifenex PSE 60 (HK);",
"     </li>",
"     <li>",
"      Novahistex Expectorant with Decongestant (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8963 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22148=[""].join("\n");
var outline_f21_40_22148=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177863\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177864\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177879\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177867\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177875\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177868\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177851\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177840\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177854\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177853\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177886\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177877\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177857\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177843\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299427\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177847\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177859\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177860\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323175\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177861\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177856\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8963|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/60/6085?source=related_link\">",
"      Guaifenesin and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22149="Squamous cell ca";
var content_f21_40_22149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Well-differentiated invasive squamous cell carcinoma. Islands of cells demonstrating keratinization, prominent cell border, and nuclear pleomorphism are present. B: Squamous cell carcinoma with focal keratinization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22149=[""].join("\n");
var outline_f21_40_22149=null;
var title_f21_40_22150="Sleep-disordered breathing in COPD";
var content_f21_40_22150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleep-disordered breathing in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22150/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22150/contributors\">",
"     Peter C Gay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22150/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22150/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22150/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22150/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22150/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/40/22150/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic obstructive pulmonary disease (COPD) frequently suffer from nocturnal alterations in ventilation and gas exchange, which are generally unrelated to the development of bronchospasm or to changes in airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The respiratory effects of sleep in patients with COPD, including a diagnostic approach to sleep-disordered breathing in this population, will be presented here. Treatment of sleep-disordered breathing in patients with COPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9030?source=see_link\">",
"     \"Treatment of sleep-disordered breathing in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SLEEP AND VENTILATION IN COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in chemoresponsiveness to CO",
"    <sub>",
"     2",
"    </sub>",
"    and alterations in arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    occur even in normal individuals during sleep, but these changes are accentuated in patients with COPD. In normal individuals, minute ventilation and ventilatory responsiveness to CO",
"    <sub>",
"     2",
"    </sub>",
"    progressively decrease as the depth of sleep increases, with arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    rising to a maximum during rapid eye movement (REM) sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/3\">",
"     3",
"    </a>",
"    ]. However, this decrease in ventilation does not generally result in significant hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocturnal ventilatory drive is affected in a similar fashion, but to a larger extent, in patients with COPD compared to normal individuals. Thus, they experience a much greater decrease in the slope of the relationship between ventilation and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    during sleep, which can result in clinically significant alveolar hypoventilation with resulting hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of sleep on minute ventilation and the pattern of breathing was demonstrated in five non-hypercapnic patients with hyperinflation due to severe emphysema (mean FEV1 1.1 L; awake SaO",
"    <sub>",
"     2",
"    </sub>",
"    91 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients were sleep-deprived and observed during wakefulness and while asleep in a body plethysmograph. Sleep did not reduce the breathing frequency or functional residual capacity (FRC), but minute ventilation fell by an average of 35 percent, a change that was accounted for entirely by a parallel decrease in tidal volume. Reduced respiratory neuromuscular output and increases in upper airway resistance contributed to these changes, and were progressive as the depth of sleep increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oxygenation during sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant reductions in nocturnal oxygen saturation can occur in patients with COPD because of alveolar hypoventilation (as noted above), worsening of ventilation-perfusion mismatching, reduction of functional residual capacity, and increased upper airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/7,8,10-13\">",
"     7,8,10-13",
"    </a>",
"    ]. The changes are most profound during REM sleep, when reductions in PaO",
"    <sub>",
"     2",
"    </sub>",
"    to levels as low as 20 mmHg have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several associations or predictors of nocturnal desaturation in COPD have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a serial study over several years, nonobese patients with moderate to severe COPD were more likely to demonstrate REM desaturation if they also showed a progressive decline in arterial blood gases [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/15\">",
"       15",
"      </a>",
"      ]. No acute infection or deterioration in spirometric parameters accounted for the development of REM desaturation over time in these patients.",
"     </li>",
"     <li>",
"      In one study, hypercapnic patients with severe chronic bronchitis (so-called \"blue bloaters\"; mean FEV1 0.58 L, with awake PaO",
"      <sub>",
"       2",
"      </sub>",
"      47 mmHg and PaCO",
"      <sub>",
"       2",
"      </sub>",
"      51 mmHg) showed much more severe nocturnal hypoxemia (nadir nocturnal SaO",
"      <sub>",
"       2",
"      </sub>",
"      39 versus 78 percent) than did nonhypercapnic patients with emphysema (so-called \"pink puffers\"; mean FEV1 0.75 L, with PaO",
"      <sub>",
"       2",
"      </sub>",
"      72 mmHg and PaCO",
"      <sub>",
"       2",
"      </sub>",
"      36 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/16\">",
"       16",
"      </a>",
"      ]. However, differences in body mass were not reported, and it is not clear if some subjects also had obstructive sleep apnea or obesity hypoventilation syndrome.",
"     </li>",
"     <li>",
"      Patients with COPD who experience oxyhemoglobin desaturation during exercise were more likely to develop nocturnal hypoxemia in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/17\">",
"       17",
"      </a>",
"      ]. However, a correlation between exercise and nocturnal desaturation in COPD has not been consistently found in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nocturnal oxygen desaturation can have adverse consequences in patients with COPD. Specifically, nocturnal oxygen desaturation is associated with an increased likelihood that a patient will develop chronic respiratory failure requiring long-term oxygen therapy (LTOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/19\">",
"     19",
"    </a>",
"    ]. Mortality is increased among women who require LTOT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sleep quality in COPD patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;COPD patients are more likely to report regular use of hypnotic medications, difficulty falling or staying asleep, and daytime sleepiness. Nocturnal desaturation is associated with more sleep fragmentation and arousals most notably during REM sleep. The more severe the COPD and hypoxemia, the less total and REM sleep time. LTOT has minimal effect on sleep quality (",
"    <a class=\"graphic graphic_figure graphicRef80457 \" href=\"UTD.htm?15/50/16174\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/21\">",
"     21",
"    </a>",
"    ]. Other common co-existing medical problems such as gastroesophageal reflux can contribute to sleep disruption, and need to be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/15,21,22\">",
"     15,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SLEEP DISORDERS AND COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal hypoxemia and hypoventilation may occur in patients with severe COPD alone, but such changes are usually most pronounced when coexisting obesity and obstructive sleep apnea (OSA, a disorder characterized by obstructive apneas and hypopneas) are present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In such cases, which are often referred to as the overlap syndrome, the effects of obesity and OSA are usually predominant, and treatment that effectively eliminates OSA is often sufficient to reduce the consequences of daytime hypercapnia and right ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/23,25-28\">",
"     23,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several reports have examined the frequency of the association between OSA and COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/5,29-31\">",
"     5,29-31",
"    </a>",
"    ]. Screening of patients with severe COPD suggests that up to 20 percent have coexisting OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/30\">",
"     30",
"    </a>",
"    ]. The Sleep Heart Health Study was done to examine the relationship between cardiovascular disease and obstructive sleep apnea, but an ancillary investigation focused on patients with predominantly mild COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/32\">",
"     32",
"    </a>",
"    ]. They found that the prevalence of sleep apnea hypopnea (SAH) was not greater with versus without mild COPD (22.3 versus 28.9 percent, respectively) using a respiratory disturbance index (RDI) threshold &gt;10. Mild COPD alone showed minimally altered sleep quality. The prevalence of OSA may increase with increasing alcohol intake, although modest evening ingestion of alcohol appears to be well tolerated, even among patients with severe COPD, in the absence of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, undiagnosed COPD may be present in &ge;10 percent of patients with OSA. As an example, one prospective study found that 11 percent of patients with a confirmed diagnosis of OSA had an obstructive pattern on spirometry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/29\">",
"     29",
"    </a>",
"    ]. These patients with airflow obstruction were male, generally older, and had a higher PaCO",
"    <sub>",
"     2",
"    </sub>",
"    and pulmonary artery pressure and a lower PaO",
"    <sub>",
"     2",
"    </sub>",
"    when compared to those without daytime airflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications for evaluation of sleep disordered breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several symptoms and findings in a patient with COPD should raise the clinician's index of suspicion for sleep disordered breathing, and should prompt consideration of a diagnostic evaluation. Any symptoms and signs suggestive of OSA should lead to further investigation, particularly given the high frequency of sleep-disordered breathing in the general population. Snoring, daytime hypersomnolence, obesity or significant weight gain, and the presence of physical features suggesting OSA are all associated with nocturnal breathing disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings in patients with COPD should heighten clinical concern for possible nocturnal hypoxemia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypercapnia during wakefulness",
"     </li>",
"     <li>",
"      Moderate to severe daytime hypoxemia",
"     </li>",
"     <li>",
"      Pulmonary and systemic hypertension",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is useful to review the history for symptoms suggestive of sleep disordered breathing in patients with COPD who experience progressive worsening of hypoxemia and hypercapnia during wakefulness, despite stable spirometry. A suggestive history in these individuals should prompt consideration of objective testing for the presence of sleep disordered breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Screening for sleep disordered breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of oxygen saturation by pulse oximetry (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) has proven invaluable as a screening and monitoring device for a variety of clinical applications, including sleep-related breathing disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/35\">",
"     35",
"    </a>",
"    ]. One study, for example, evaluated patients with COPD and an FEV1 less than 1.5 L [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/36\">",
"     36",
"    </a>",
"    ]. When an awake SpO",
"    <sub>",
"     2",
"    </sub>",
"    below 92 percent was used as a threshold, the sensitivity and specificity were 100 and 86 percent, respectively, for detecting patients with PaO",
"    <sub>",
"     2",
"    </sub>",
"    below 56 mmHg who therefore qualify for long term oxygen therapy (LTOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others have expressed concern about oximetry use since there is not and established reference range. One study showed wide variation in clinician interpretation of nocturnal oximetry studies and concluded that \"use and opinions regarding overnight pulse oximetry monitoring calls into question its clinical utility and underscores a need for standardization of presentation, training and interpretation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, awake oxygen saturation is not a good predictor of the presence or severity of nocturnal oxygen desaturation. Although one study demonstrated that patients with COPD had an average sleep-related decline in SpO",
"    <sub>",
"     2",
"    </sub>",
"    of 9 percent, individual reductions in SpO",
"    <sub>",
"     2",
"    </sub>",
"    could not be predicted on the basis of awake SpO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More complex diagnostic investigations, including arterial blood gas testing and overnight polysomnography, are indicated in several clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progressive hypoventilation (worsening hypercapnia)",
"     </li>",
"     <li>",
"      Suspected upper airway obstruction, ie, coexisting OSA",
"     </li>",
"     <li>",
"      Continued clinical deterioration despite the use of oxygen therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nocturnal end-tidal PCO",
"    <sub>",
"     2",
"    </sub>",
"    has been used under some circumstances to detect nocturnal apneas and hypopneas in patients with snoring and daytime hypersomnolence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/39\">",
"     39",
"    </a>",
"    ], but nearly all cases need further evaluation with a formal overnight study in a sleep laboratory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;COPD can result in significant sleep-related hypoxemia and hypercarbia, even in the absence of OSA or obesity hypoventilation syndrome. Thus, the utility of overnight oximetry in the diagnosis of OSA is limited in patients with COPD. When the clinical suspicion for OSA in a patient with COPD is high (eg, daytime hypersomnolence, witnessed apneas), most clinicians would recommend immediate full laboratory polysomnography. Patients with significant hypercapnia (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;50 mmHg) should initially be treated with CPAP, but they should be reevaluated with arterial blood gases and overnight oximetry after a two to three week adjustment period. However, in some cases, the clinical concern for significant ongoing nocturnal hypoventilation or obstructive sleep apnea warrants immediate full laboratory polysomnography with titration.",
"   </p>",
"   <p>",
"    The question of multi-channel home monitoring in patients with severe chronic obstructive pulmonary disease is now being addressed aggressively, but the precise role remains undetermined and is often more specifically directed by regional reimbursement practices [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22150/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/1\">",
"      Urbano F, Mohsenin V. Chronic obstructive pulmonary disease and sleep: the interaction. Panminerva Med 2006; 48:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/2\">",
"      Casey KR, Cantillo KO, Brown LK. Sleep-related hypoventilation/hypoxemic syndromes. Chest 2007; 131:1936.",
"     </a>",
"    </li>",
"    <li>",
"     Phillipson EA, Bowes G. Control of breathing during sleep. In: Handbook of Physiology, Cherniack NS, Widdicombe JG (Eds), Section 3: The Respiratory System; Vol. II, Control of Breathing, American Physiologic Society, Bethesda, MD, 1986, pp. 649-689.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/4\">",
"      Douglas NJ, White DP, Weil JV, et al. Hypoxic ventilatory response decreases during sleep in normal men. Am Rev Respir Dis 1982; 125:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/5\">",
"      O'Donoghue FJ, Catcheside PG, Ellis EE, et al. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors. Eur Respir J 2003; 21:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/6\">",
"      Meurice JC, Marc I, S&eacute;ri&egrave;s F. Influence of sleep on ventilatory and upper airway response to CO2 in normal subjects and patients with COPD. Am J Respir Crit Care Med 1995; 152:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/7\">",
"      Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/8\">",
"      Gay PC. Chronic obstructive pulmonary disease and sleep. Respir Care 2004; 49:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/9\">",
"      McNicholas WT. Impact of sleep in COPD. Chest 2000; 117:48S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/10\">",
"      Ballard RD, Clover CW, Suh BY. Influence of sleep on respiratory function in emphysema. Am J Respir Crit Care Med 1995; 151:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/11\">",
"      Kutty K. Sleep and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2004; 10:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/12\">",
"      Fanfulla F, Cascone L, Taurino AE. Sleep disordered breathing in patients with chronic obstructive pulmonary disease. Minerva Med 2004; 95:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/13\">",
"      Plywaczewski R, Sliwinski P, Nowinski A, et al. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 2000; 117:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/14\">",
"      Fletcher EC, Scott D, Qian W, et al. Evolution of nocturnal oxyhemoglobin desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1991; 144:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/15\">",
"      Calverley PM, Brezinova V, Douglas NJ, et al. The effect of oxygenation on sleep quality in chronic bronchitis and emphysema. Am Rev Respir Dis 1982; 126:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/16\">",
"      Fletcher EC, Gray BA, Levin DC. Nonapneic mechanisms of arterial oxygen desaturation during rapid-eye-movement sleep. J Appl Physiol 1983; 54:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/17\">",
"      Mulloy E, Fitzpatrick M, Bourke S, et al. Oxygen desaturation during sleep and exercise in patients with severe chronic obstructive pulmonary disease. Respir Med 1995; 89:193.",
"     </a>",
"    </li>",
"    <li>",
"     Phillipson EA. Sleep disorders. In: Textbook of Respiratory Medicine, Vol. II, Murray JF, Nadel JA (Eds), WB Saunders, Philadelphia 1988. p.1841-1860.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/19\">",
"      Sergi M, Rizzi M, Andreoli A, et al. Are COPD patients with nocturnal REM sleep-related desaturations more prone to developing chronic respiratory failure requiring long-term oxygen therapy? Respiration 2002; 69:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/20\">",
"      Machado MC, Krishnan JA, Buist SA, et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/21\">",
"      Fleetham J, West P, Mezon B, et al. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis 1982; 126:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/22\">",
"      Catterall JR, Douglas NJ, Calverley PM, et al. Transient hypoxemia during sleep in chronic obstructive pulmonary disease is not a sleep apnea syndrome. Am Rev Respir Dis 1983; 128:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/23\">",
"      Brown LK. Sleep-related disorders and chronic obstructive pulmonary disease. Respir Care Clin N Am 1998; 4:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/24\">",
"      Bradley TD. Right and left ventricular functional impairment and sleep apnea. Clin Chest Med 1992; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/25\">",
"      Resta O, Foschino Barbaro MP, Brindicci C, et al. Hypercapnia in overlap syndrome: possible determinant factors. Sleep Breath 2002; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/26\">",
"      de Miguel J, Cabello J, S&aacute;nchez-Alarcos JM, et al. Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome. Sleep Breath 2002; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/27\">",
"      Radwan L, Maszczyk Z, Koziorowski A, et al. Control of breathing in obstructive sleep apnoea and in patients with the overlap syndrome. Eur Respir J 1995; 8:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/28\">",
"      Chaouat A, Weitzenblum E, Krieger J, et al. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995; 151:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/29\">",
"      Lin CC, Huang WC. [Sleep quality and nocturnal hypoxemia in patients with chronic obstructive pulmonary disease]. J Formos Med Assoc 1992; 91 Suppl 3:S232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/30\">",
"      Brander PE, Kuitunen T, Salmi T, Partinen M. Nocturnal oxygen saturation in advanced chronic obstructive pulmonary disease after a moderate dose of ethanol. Eur Respir J 1992; 5:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/31\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/32\">",
"      Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003; 167:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/33\">",
"      Penzel T, Peter JH. Ambulatory diagnosis of sleep-related breathing disorders. Sleep 1992; 15:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/34\">",
"      Ferini-Strambi L, Zucconi M, Palazzi S, et al. Snoring and nocturnal oxygen desaturations in an Italian middle-aged male population. Epidemiologic study with an ambulatory device. Chest 1994; 105:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/35\">",
"      Tobert DG, Gay PC. New directions for pulse oximetry in sleep disorders. Mayo Clin Proc 1995; 70:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/36\">",
"      Roberts CM, Bugler JR, Melchor R, et al. Value of pulse oximetry in screening for long-term oxygen therapy requirement. Eur Respir J 1993; 6:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/37\">",
"      Ramsey R, Mehra R, Strohl KP. Variations in physician interpretation of overnight pulse oximetry monitoring. Chest 2007; 132:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/38\">",
"      Mohsenin V, Guffanti EE, Hilbert J, Ferranti R. Daytime oxygen saturation does not predict nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 1994; 75:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/39\">",
"      Vos PJ, Folgering HT, van Herwaarden CL. Nocturnal end-tidal PCO2 to detect apnoeas and hypopnoeas in sleep-disordered breathing. Physiol Meas 1993; 14:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22150/abstract/40\">",
"      White DP, Gibb TJ, Wall JM, Westbrook PR. Assessment of accuracy and analysis time of a novel device to monitor sleep and breathing in the home. Sleep 1995; 18:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7680 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22150=[""].join("\n");
var outline_f21_40_22150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SLEEP AND VENTILATION IN COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oxygenation during sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sleep quality in COPD patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SLEEP DISORDERS AND COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications for evaluation of sleep disordered breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Screening for sleep disordered breathing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7680|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/50/16174\" title=\"figure 1\">",
"      COPD vs normal sleep",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9030?source=related_link\">",
"      Treatment of sleep-disordered breathing in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22151="Hemochromatosis - high power";
var content_f21_40_22151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis (high power, H&amp;E)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Innumerable hemosiderin deposits are seen in hepatocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22151=[""].join("\n");
var outline_f21_40_22151=null;
var title_f21_40_22152="Management and evaluation of wide QRS complex tachycardia in children";
var content_f21_40_22152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and evaluation of wide QRS complex tachycardia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22152/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22152/contributors\">",
"     Susan P Etheridge, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22152/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22152/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22152/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22152/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22152/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/40/22152/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia in children is generally defined as a heart rate exceeding 120 beats per minute in older children and adolescents, and 180 beats per minute in infants and young children.",
"   </p>",
"   <p>",
"    Children with tachycardia may present with hemodynamic instability, and if not emergently treated, serious morbidity or death may occur. Hemodynamic stabilization and therapy directed towards the underlying arrhythmia are critical to effectively manage these children. Once the patient is stabilized, further evaluation should be performed to identify the underlying cause of tachycardia and determine whether corrective therapy is indicated.",
"   </p>",
"   <p>",
"    The initial management of the unstable child with tachycardia includes examination of the standard electrocardiogram (ECG) and assessment of the duration of the QRS complex. The width of the QRS complex aids in determining the origin of the arrhythmia and guides initial management decisions (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Narrow QRS complex tachycardia &mdash; A narrow QRS complex (QRS duration &le;80 msec) indicates that the origin of the arrhythmia is above or within the atrioventricular (AV) node. The short QRS duration indicates rapid activation of the ventricles through the AV node and the His-Purkinje system, and eliminates ventricular tachycardia (VT) as an etiology of the increased heart rate. Causes of narrow QRS complex tachycardia include sinus tachycardia, atrial fibrillation and flutter, and most cases of supraventricular tachycardia. These conditions are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=see_link\">",
"       \"Sinus tachycardia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"       \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wide QRS complex tachycardia &mdash; With wide QRS complex (QRS duration &gt;80 msec) tachycardia, ventricular tachycardia (VT) must be first considered because VT may rapidly convert to ventricular fibrillation and result in cardiac arrest. Wide QRS complex tachycardia may also be seen in patients with supraventricular tachycardia (SVT) with an aberrant conduction systems or antidromic AV reentrant tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management and evaluation of wide QRS complex tachycardia in children will be presented here. The causes of wide QRS complex tachycardia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"     \"Causes of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a discussion on the acute management of a child who presents with wide QRS complex tachycardia and is based upon the 2005 American Heart Association, American Academy of Pediatrics, and International Liaison Committee on Resuscitation",
"    <span class=\"nowrap\">",
"     (AHA/AAP/ILCOR)",
"    </span>",
"    guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assessment of the patient's hemodynamic status takes precedence over any diagnostic evaluation. A patient who is unresponsive or pulseless is in cardiac arrest, and cardiopulmonary resuscitation based upon",
"    <span class=\"nowrap\">",
"     AHA/AAP/ILCOR",
"    </span>",
"    should be initiated immediately (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Unstable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable patients with tachycardia, palpable pulses, and poor perfusion but conscious are at risk for cardiac arrest, especially if the underlying arrhythmia is VT. In these patients, we recommend using the following",
"    <span class=\"nowrap\">",
"     AHA/AAP/ILCOR",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the airway and circulatory system. Provide airway management, oxygenation, and ventilation as needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"       \"Assessment of perfusion in pediatric resuscitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attach an ECG monitor or defibrillator with a rhythm display. The QRS duration for the patient is determined from the ECG rhythm.",
"     </li>",
"     <li>",
"      If the QRS is greater than 80 msec (wide QRS complex tachycardia), the origin of the arrhythmia is assumed to be ventricular.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The child is treated with synchronized cardioversion (0.5 joules to 1 joule per kg) to convert the arrhythmia to normal sinus rhythm. Sedation is suggested if the patient is conscious and it does not delay cardioversion.",
"   </p>",
"   <p>",
"    If it does not delay cardioversion and intravenous access is available, an empiric intravenous dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose 6 mg) may be given by rapid bolus. Adenosine is effective in treating patients with SVT and is not as effective in most patients with VT. It is beneficial in patients with right ventricular outflow tract tachycardia that is thought to be due to cAMP-mediated triggered activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, it should only be used when SVT with aberrant conduction is suspected or when adenosine-sensitive right ventricular outflow tract is known or suspected.",
"   </p>",
"   <p>",
"    If the initial shock is not effective, a second cardioversion with an increased dose (2 joule per kg) is administered.",
"   </p>",
"   <p>",
"    If the rhythm is not consistent with torsades de pointes and if the second cardioversion is ineffective, antiarrhythmic therapy (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    ) can be used before a third cardioversion attempt.",
"   </p>",
"   <p>",
"    Because there is more clinical experience with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    in the successful treatment of children with tachyarrhythmias, we initially use amiodarone at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose 300 mg) administered intravenously over 20 to 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Adverse effects are common and include hypotension, vomiting, bradycardia, atrioventricular block, and nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    can be given intravenously at a dose of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 30 to 60 minutes, although there are limited clinical data in its use in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/1\">",
"     1",
"    </a>",
"    ]. One should not routinely administer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    and procainamide together because both can prolong the QT interval resulting in heart block. If available, consultation with a clinician experienced in treating children with arrhythmias is advised.",
"   </p>",
"   <p>",
"    If the rhythm is consistent with torsades de pointes, intravenous magnesium at a dose of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient who is hemodynamically stable, additional time can be given to determine whether wide QRS complex tachycardia is due to VT or SVT with aberrant intraventricular conduction. Differentiation between the mechanisms guides further management choices in terminating the arrhythmia. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"     \"Causes of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION OF STABLE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a stable patient with wide QRS complex tachycardia, the goals of the initial evaluation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To determine if the wide QRS complex tachycardia originates from the ventricles, or is supraventricular with aberrant intraventricular conduction. The treatment and long-term prognosis differs between children with VT versus those with SVT. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation of ECG'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      To determine what therapeutic intervention(s) is required acutely.",
"     </li>",
"     <li>",
"      In addition, the initial evaluation will provide clues to aid in making a specific diagnosis, and determine the need of further testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      corrective intervention. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chronic management of ventricular tachycardia'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"       \"Management of supraventricular tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Laboratory testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is directed towards identifying patients with cardiac conditions (such as congenital long QT syndrome, acquired QT prolongation, or Brugada syndrome) that are associated with ventricular tachycardia (VT). These patients who are at risk for sudden cardiac death require further evaluation and therapeutic interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"     \"Causes of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of heart disease &mdash; A child with congenital heart disease, especially one has undergone cardiac surgery, is at increased risk for VT and sudden cardiac death.",
"     </li>",
"     <li>",
"      Medications &mdash; Many medications are associated with acquired QT prolongation and VT, including antiarrhythmic drugs (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"       quinidine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"       procainamide",
"      </a>",
"      ), some nonsedating antihistamines (terfenadine or astemizole), macrolide antibiotics, or antipsychotic and antidepressant medications (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 1",
"      </a>",
"      ). In addition, antiarrhythmic drugs can cause aberrancy during supraventricular tachycardia, resulting in wide QRS complex tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"       \"Myocardial action potential and action of antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of metabolic disorders &mdash; Patients who develop hypokalemia or hypomagnesemia are at increased risk for acquired QT prolongation and VT (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 1",
"      </a>",
"      ). These conditions may be due to excessive urinary losses of these elements from drugs or renal tubular disorders, or inadequate dietary intake. Patients with anorexia nervosa also have prolonged QT intervals, which may cause arrhythmias and sudden death. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=see_link&amp;anchor=H31379357#H31379357\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Cardiovascular'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history &mdash; A family history of sudden cardiac death or sudden infant death syndrome may be elicited in patients with inherited cardiac disorders associated with VT. These include congenital long QT syndrome, Brugada syndrome, short QT syndrome, arrhythmogenic right ventricular cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, or hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Sudden infant death syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"       \"Causes of wide QRS complex tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac symptoms &mdash; Symptoms generally are not useful in determining the specific underlying diagnosis but are important in assessing the severity of hemodynamic compromise and the need for intervention. A history of a previous episode of syncope and the clinical situation surrounding the event are important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms related to tachycardia include palpitations, lightheadedness, weakness, diaphoresis, chest discomfort or pain, or syncope. In infants or nonverbal young children, parents may report nonspecific symptoms of poor feeding, irritability, and loss of consciousness. Seizures may be secondary to unwitnessed syncope.",
"   </p>",
"   <p>",
"    Symptoms may be related to left ventricular heart dysfunction due to associated heart disease (such as hypertrophic or dilated cardiomyopathy or myocarditis) rather than to the elevated heart rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is important, as it provides an assessment of the hemodynamic status of the patient and guides acute management decisions.",
"   </p>",
"   <p>",
"    Even if a patient is initially stable with adequate perfusion, children with wide QRS complex tachycardia can quickly decompensate and become hemodynamically unstable. Thus, the examination initially focuses upon and continues to monitor for signs of impending respiratory failure or compensated shock as long as the wide QRS complex tachycardia is present. Acute intervention initially with cardioversion should be considered in patients with any of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased respiratory rate, signs of respiratory distress (eg, nasal flaring, grunting, retractions, or grunting), or signs of inadequate respiratory effort (eg, decreased respiratory rate, effort or excursion)",
"     </li>",
"     <li>",
"      Cool extremities, prolonged capillary refill, or weak peripheral pulses compared with central pulses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination also focuses upon detecting signs of cardiac dysfunction or disease (eg, cardiac failure or structural heart disease) that may provide clues to the underlying cause of tachycardia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory &mdash; Increased respiratory rate and effort",
"     </li>",
"     <li>",
"      Liver &mdash; Hepatomegaly",
"     </li>",
"     <li>",
"      Cardiac &mdash; Gallop",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      murmur",
"     </li>",
"     <li>",
"      Peripheral edema (rare in infants)",
"     </li>",
"     <li>",
"      Dysmorphic features suggesting a syndrome that can be associated with ventricular arrhythmias such as Barth syndrome, Timothy syndrome (long QT type 8 disorder), and Andersen Tawil syndrome (long QT type 7 disorder). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link&amp;anchor=H10#H10\">",
"       \"Inherited syndromes associated with cardiac disease\", section on 'Barth's syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link&amp;anchor=H5900715#H5900715\">",
"       \"Genetics of dilated cardiomyopathy\", section on 'Barth's syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H12#H12\">",
"       \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 7'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link&amp;anchor=H7#H7\">",
"       \"Causes of wide QRS complex tachycardia in children\", section on 'Channelopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H13#H13\">",
"       \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 8'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evaluation of ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with wide QRS complex tachycardia, electrocardiogram (ECG) is helpful in differentiating between VT and SVT. However, definitive diagnosis is not always possible and may be time-consuming, especially for physicians unfamiliar with the criteria for distinguishing VT from SVT.",
"   </p>",
"   <p>",
"    If there are any questions regarding the patient's stability, detailed ECG evaluation should be deferred in favor of urgent therapy. If time allows, an ECG should be obtained for later review. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Unstable patient'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To perform an adequate ECG analysis, both a 12-lead ECG and a rhythm strip should be obtained. If available, a previous ECG when the patient was in normal sinus rhythm is useful.",
"   </p>",
"   <p>",
"    The presence of AV dissociation (atrial activity that is independent of ventricular activity) generally establishes VT as the underlying mechanism of the wide QRS complex tachycardia. In AV dissociation, dissociated P waves are recorded at a rate slower than the ventricular rate (",
"    <a class=\"graphic graphic_waveform graphicRef52123 \" href=\"UTD.htm?5/61/6104\">",
"     waveform 1",
"    </a>",
"    ). Capture beats (dissociated P wave activates the ventricle prior to the next VT complex) and fusion beats (simultaneous activation of the ventricle by the dissociated P wave and the ventricle) may be seen in AV dissociation (",
"    <a class=\"graphic graphic_waveform graphicRef72600 \" href=\"UTD.htm?4/46/4840\">",
"     waveform 2",
"    </a>",
"    ). However, in some cases of VT, there is no AV dissociation because of retrograde conduction from the ventricle to the atrium.",
"   </p>",
"   <p>",
"    Other ECG features that are useful in distinguishing VT from SVT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Axis &mdash; Right superior axis (-90 to &plusmn;180) or an axis shift of more than 40 degrees than the axis in normal sinus rhythm are suggestive of VT.",
"     </li>",
"     <li>",
"      QRS duration &mdash; Wider QRS complex is more suggestive of VT. In adults a QRS duration &gt;160 msec is a strong predictor of VT. However, in infants and small children, the QRS duration may be much less wide, especially LV fascicular VT.",
"     </li>",
"     <li>",
"      Concordance &mdash; Concordance is present when the QRS complexes in all six precordial leads (V1 through V6) are monophasic with the same polarity. They can either all be entirely positive with tall, monophasic R waves, or all be entirely negative with deep monophasic QS complexes. If any of the six leads has a biphasic QRS (qR or RS complexes), concordance is not present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"       \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Negative concordance is strongly suggestive of VT. Rarely, SVT with LBBB aberrancy will demonstrate negative concordance, but there is almost always some evidence of an R wave in the lateral leads.",
"     </li>",
"     <li>",
"      Positive concordance is most often due to VT but can also occur in the relatively rare case of antidromic AVRT with a left posterior accessory pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation of ECG in wide QRS complex tachycardia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\", section on 'Evaluation of the electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum potassium and magnesium should be measured as part of the initial evaluation, because both hypokalemia and hypomagnesemia can prolong QT interval resulting in VT.",
"   </p>",
"   <p>",
"    In patients taking",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"     quinidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    , plasma concentrations should be measured to determine whether drug toxicity is a causative factor for tachyarrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONTINUED MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After determining the origin of the wide QRS complex tachycardia in the stable patient, treatment can be targeted to the specific arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients with VT, the",
"    <span class=\"nowrap\">",
"     AHA/AAP/ILCOR",
"    </span>",
"    guidelines recommend that intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose 300 mg) be given slowly over 20 to 60 minutes to terminate VT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional doses can be given in patients who remain in VT and do not have signs of toxicity. ECG and blood pressure monitoring are required as amiodarone can prolong the QT interval and cause hypotension.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    is not available, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    can be administered as a 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus over 30 to 60 minutes. Similar to amiodarone, ECG and blood pressure monitoring are required.",
"   </p>",
"   <p>",
"    Because both medications can prolong the QT interval,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    should not be administered together unless care is supervised by a clinician with expertise in treating children with arrhythmias.",
"   </p>",
"   <p>",
"    In left ventricular fascicular VT, the drug of choice is a calcium channel blocking agent, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/14/16617?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     verapamil",
"    </a>",
"    . These should only be given with a pediatric cardiologist in attendance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes of wide QRS complex tachycardia in children\", section on 'Idiopathic left ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The VT in patients with",
"    <strong>",
"     catecholaminergic polymorphic ventricular tachycardia",
"    </strong>",
"    (CPVT) is described as bidirectional and is thought to be the result of triggered activity. Thus, this tachycardia may be less responsive to electrical cardioversion until it degenerates into VF. In these patients, there may be multiple episodes of VT and electrical storm. Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     esmolol",
"    </a>",
"    , a beta blocker, may result in resolution of the VT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stable patients with SVT and aberrant intraventricular conduction resulting in wide QRS complex tachycardia are managed in the same manner as other patients with SVT.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AHA/AAP/ILCOR",
"    </span>",
"    guidelines recommend in a hemodynamically stable child, vagal maneuvers should be attempted to terminate SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/1\">",
"     1",
"    </a>",
"    ]. For an infant, this consists of the application of an ice bag to the face for 15 to 30 seconds. In an older child, the vagal maneuver should consist of bearing down (Valsalva maneuver) for 15 to 20 seconds. A continuous ECG rhythm strip should be obtained during the maneuver.",
"   </p>",
"   <p>",
"    If the vagal maneuver does not convert SVT to normal rhythm, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    should be administered at a dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    followed by a rapid saline flush. If the rhythm does not convert with the initial dose, adenosine is repeated with increases to a maximum dose of 0.25 to 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or a total dose of 12 mg.",
"   </p>",
"   <p>",
"    If the SVT is unresponsive to vagal maneuvers or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     adenosine",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    , dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose 300 mg) over 20 to 60 minutes, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/18/38182?source=see_link\">",
"     procainamide",
"    </a>",
"    , dose of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 30 to 60 minutes, can be used. In addition, consultation with a clinician with expertise in treating children with arrhythmias is recommended.",
"   </p>",
"   <p>",
"    The evaluation and management of supraventricular tachycardia are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=see_link\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"     \"Management of supraventricular tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHRONIC MANAGEMENT OF VENTRICULAR TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the acute episode of VT is terminated, the clinician must decide whether further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corrective therapy such as ablation or the placement of an implantable cardioverter-defibrillator are indicated. These decisions need to be made by a clinician with expertise in pediatric electrophysiology.",
"   </p>",
"   <p>",
"    Answers to the following questions are used to guide the long-term evaluation and management of children who present with VT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the tachycardia persistent or recurs frequently?",
"     </li>",
"     <li>",
"      During episodes of tachycardia, is the child symptomatic and how long are the episodes?",
"     </li>",
"     <li>",
"      Is there evidence of cardiac disease or dysfunction?",
"     </li>",
"     <li>",
"      In children with cardiac disease, what is the natural history of the specific disorder? Is there an increased risk of sudden cardiac death or life-threatening arrhythmias?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the resolution of VT, evaluation is focused upon detecting underlying cardiac disease, if present, and to make the diagnosis. Patients who are symptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have recurrent episodes require more extensive evaluation, as they are at higher risk for underlying cardiac disease. All children with VT should be referred to a pediatric cardiologist for evaluation and management.",
"   </p>",
"   <p>",
"    An initial evaluation using echocardiography and ECG in all patients with VT will detect several cardiac disorders (",
"    <a class=\"graphic graphic_algorithm graphicRef66547 \" href=\"UTD.htm?35/28/36302\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography should be performed to evaluate cardiac structure and function in all patients.",
"     </li>",
"     <li>",
"      Analysis of ECG while the patient is in sinus rhythm may identify many cardiac disorders associated with wide QRS complex tachycardia based upon their characteristic ECG findings. These include long QT syndrome, short QT syndrome, and sometimes arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome, all of which are associated with early sudden cardiac death, and require further evaluation and therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link\">",
"       \"Causes of wide QRS complex tachycardia in children\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other diagnostic studies are performed in patients when the diagnosis remains uncertain. These include magnetic resonance imaging, cardiac catheterization, 24-hour Holter monitoring, exercise and electrophysiologic testing, and genetic testing for possible channelopathies, arrhythmogenic right ventricular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia. Indications and utilization of each test vary among centers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of wide QRS complex tachycardia in children\", section on 'Ventricular tachycardia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In our practice, these studies are performed in patients when the diagnosis remains uncertain after a complete noninvasive evaluation, and who are symptomatic during episodes of VT, have recurrent episodes or a family history of unexpected early death, or in whom a catheter ablation is considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no general consensus regarding the chronic management of children who present with VT. In general, asymptomatic children with normal cardiac structure and function are often followed closely without any therapeutic intervention. In contrast, patients who are symptomatic or have a disease associated with a high risk of sudden cardiac disease are treated.",
"   </p>",
"   <p>",
"    Treatment options include drug therapy, catheter or surgical ablation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    placement of an implantable cardioverter-defibrillator (ICD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In some circumstances, especially in patients at high risk for sudden cardiac death, medications are ineffective and ICD implantation is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It remains unclear whether asymptomatic patients with cardiac pathology and evidence of VT should be treated. The clinician must balance the side effects of therapy or complications of therapeutic interventions against the risk of a life-threatening arrhythmia. Management will be dependent upon the underlying cause of VT, and the local expertise, experience, medical costs, and available technology of the medical center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, in children who present with tachycardia, the assessment of the patient's hemodynamic status takes precedence over any diagnostic evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient who is unresponsive or pulseless, cardiopulmonary resuscitation is required. We suggest the child is treated according to the Pediatric Advance Life Support guidelines developed by the American Heart Association, American Academy of Pediatrics, and the International Liaison Committee on Resuscitation",
"      <span class=\"nowrap\">",
"       AHA/AAP/ILCOR",
"      </span>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"       \"Basic life support in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an unstable patient (tachycardia, palpable pulses, and poor perfusion but conscious) with wide QRS complex tachycardia, we recommend synchronized cardioversion (0.5 joules to 1 joule per kg) as the initial therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Unstable patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a stable patient with wide QRS complex tachycardia, an evaluation that includes electrocardiogram (ECG) analysis, may proceed to determine the nature of the underlying arrhythmia and guide specific therapy as follows: (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Evaluation'",
"    </a>",
"    above)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ECG finding of a wide QRS tachycardia with atrioventricular (AV) dissociation establishes ventricular tachycardia (VT) as the underlying mechanism of the arrhythmia (",
"      <a class=\"graphic graphic_waveform graphicRef52123 \" href=\"UTD.htm?5/61/6104\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation of ECG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In stable patients with VT, we suggest using the",
"      <span class=\"nowrap\">",
"       AHA/AAP/ILCOR",
"      </span>",
"      regimen of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 300 mg) given over 20 to 60 to terminate the tachyarrhythmia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Sedation and cardioversion also are useful in this situation and may be safer if there is a concern about cardiac dysfunction or the presence of LQTS or acquired QT prolongation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with SVT and aberrant intraventricular conduction, we suggest using the",
"      <span class=\"nowrap\">",
"       AHA/AAP/ILCOR",
"      </span>",
"      regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Vagal maneuvers are used initially to terminate the tachycardia. If the vagal maneuver does not convert SVT to normal rhythm, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"       adenosine",
"      </a>",
"      can be administered in an initial bolus dose of 0.1",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"       \"Management of supraventricular tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chronic management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the acute episode of VT is terminated; each patient should be evaluated to detect any underlying cardiac disease. The assessment includes echocardiography and an ECG analysis while the patient is in sinus rhythm. Indications for further diagnostic testing (eg, magnetic resonance imaging, cardiac catheterization, 24-hour Holter monitoring, and an electrophysiologic study) vary among centers. In our practice, these tests are performed in patients, where the diagnosis remains uncertain after the initial evaluation, who are symptomatic during episodes of VT, have recurrent episodes, or there is a family history of unexpected early death. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no general consensus regarding the chronic management of children who present with VT. The following guidelines are based upon our clinical practice. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest no therapeutic intervention but close monitoring in asymptomatic children with a normal resting heart rate, normal ECG, normal cardiac structure and function, and without a worrisome family history (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22152/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We suggest that patients who are symptomatic or have a disease associated with a high risk of sudden cardiac disease be treated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment options include drug therapy, catheter or surgical ablation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      placement of an implantable cardioverter-defibrillator (ICD). The choice of treatment is dependent upon the underlying diagnosis, and the local expertise and availability at each center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains unclear whether or not asymptomatic patients with cardiac pathology and evidence of ventricular ectopy should be treated. In our center, the decision for intervention is based upon the patient's cardiac diagnosis and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    risk of sudden cardiac death.",
"   </p>",
"   <p>",
"    The chronic management of SVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of supraventricular tachycardia in children\", section on 'Chronic therapy'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/1\">",
"      American Heart Association. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: pediatric advanced life support. Pediatrics 2006; 117:e1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/2\">",
"      Lerman BB, Belardinelli L, West GA, et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986; 74:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/3\">",
"      Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/4\">",
"      Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 1994; 74:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/5\">",
"      Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/6\">",
"      Tanel RE, Walsh EP, Triedman JK, et al. Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients. J Pediatr 1997; 131:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/7\">",
"      Kirsh JA, Gross GJ, O'Connor S, et al. Transcatheter cryoablation of tachyarrhythmias in children: initial experience from an international registry. J Am Coll Cardiol 2005; 45:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/8\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22152/abstract/9\">",
"      Levin MD, Stephens P, Tanel RE, et al. Ventricular tachycardia in infants with structurally normal heart: a benign disorder. Cardiol Young 2010; 20:641.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5758 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-2030A22EB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22152=[""].join("\n");
var outline_f21_40_22152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Unstable patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stable patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL EVALUATION OF STABLE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evaluation of ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONTINUED MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHRONIC MANAGEMENT OF VENTRICULAR TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stable patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chronic management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5758\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5758|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 1\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/30/42470\" title=\"algorithm 2\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/28/36302\" title=\"algorithm 3\">",
"      Evaluation vent tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5758|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 1\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5758|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/61/6104\" title=\"waveform 1\">",
"      AV dissociation tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?4/46/4840\" title=\"waveform 2\">",
"      Fusion beats tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15897?source=related_link\">",
"      Causes of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22153="Otitis media with effusion (serous otitis media) in children";
var content_f21_40_22153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Otitis media with effusion (serous otitis media) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Jerome O Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Stephen Pelton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22153/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/40/22153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media with effusion (also called serous otitis media or \"glue ear\") encompasses one of the two categories of chronic otitis media. The other category includes chronic complications of otitis media, including persistent perforation of the tympanic membrane and chronic suppurative otitis media. Chronic complications of otitis media are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otitis media with effusion (OME) is defined as the presence of middle-ear effusion (MEE) in the absence of acute signs of infection. OME most often arises following a recognized or unrecognized acute otitis media (AOM); less commonly, it may occur in association with eustachian tube obstruction without prior clinical infection. Because of the frequency of episodes of AOM during the first years of life, a young child may spend a significant proportion of those years with MEE and associated conductive hearing loss. Hearing impairment over prolonged periods of time during the first and formative years of life may affect development of speech and language [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to OME will be reviewed here. AOM and chronic complications of otitis media are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link\">",
"     \"Acute otitis media in children: Prevention of recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys of healthy children for the presence of OME have identified a high prevalence of apparently asymptomatic OME. The prevalence of effusion varies with age and the time of year. In one study of children attending a daycare center, the incidence of effusion peaked during the second year of life and was more prevalent in the winter than in the summer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/2\">",
"     2",
"    </a>",
"    ]. The episodes usually cleared within a month, and the duration of effusion was as short as one or several days. In other studies, MEE persisted for weeks to months after the onset of AOM. Young children were most likely to have persistent effusion after AOM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute otitis media in children: Treatment\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that promote persistence of MEE in patients with otitis media remain incompletely defined. Family history of otitis media, bottle as opposed to breast-feeding, daycare center attendance, and exposure to tobacco smoke are important risk factors for OME, as well as AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/3\">",
"     3",
"    </a>",
"    ]. Heritable structural abnormalities of the middle ear and eustachian tube, as demonstrated in a mouse model, also may play a role in predisposition to OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic teaching has been that the effusions of OME result from chronic inflammation in response to residual bacterial components and that the effusions frequently are sterile [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/6\">",
"     6",
"    </a>",
"    ]. However, several lines of evidence suggest that the pathogenesis may be more complicated. Factors that have been proposed to contribute to the pathogenesis of OME include biofilm formation by bacterial otopathogens, resulting in persistence and aggregation of bacteria that results in cultures of middle-ear fluid that are sterile; altered ciliary function; allergies; and gastroesophageal reflux. Histopathologically, a proliferation of mucous-secreting goblet cells is observed.",
"   </p>",
"   <p>",
"    Bacterial DNA, mRNA, and newly synthesized protein have been detected in these effusions, and viable bacteria were demonstrated within a biofilm in a chinchilla model of otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/6\">",
"     6",
"    </a>",
"    ]. Additional support for the role of biofilms in the pathogenesis of OME and recurrent otitis media was provided by a study in which mucosal biofilms were visualized in 46 of 50 (92 percent) middle-ear mucosal biopsy specimens from children undergoing tympanostomy tube placement for the treatment of OME",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent otitis media but from none of eight biopsy specimens from controls undergoing cochlear implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contribution of allergies to OME remains controversial. One study of 209 children referred to a glue",
"    <span class=\"nowrap\">",
"     ear/allergy",
"    </span>",
"    clinic in the United Kingdom found a history of allergic rhinitis, asthma, and eczema in 89, 36, and 24 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/8\">",
"     8",
"    </a>",
"    ]. In another study, myeloperoxidase, as a measure of neutrophil activation, was detected in middle-ear effusions from 86 atopic patients with OME but not in 20 children without allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastroesophageal reflux also has been hypothesized to be a cause of OME. However, investigators measuring the concentration of pepsin and pepsinogen in middle-ear fluid have reported conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], and the association between GER and OME remains speculative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bacterial pathogen is identified in approximately one out of three MEEs of children with OME who undergo myringotomy and placement of ventilating tubes, most often in children younger than two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The pathogens recovered include those that typically cause AOM: Streptococcus pneumoniae, nontypeable H. influenzae, Moraxella catarrhalis, and a variety of other agents, including Pseudomonas aeruginosa, alpha streptococci, and anaerobic bacteria.",
"   </p>",
"   <p>",
"    In general, qualitative studies suggest low bacterial densities in such effusions. Because many children who undergo placement of tympanostomy tubes have had multiple courses of antimicrobial agents, the pathogens obtained at the time of tympanostomy tube placement may include multidrug-resistant strains. Most investigators who report recovery of bacterial pathogens in OME do not find inflammatory exudates or infiltration of neutrophils in the fluid itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical signs of acute illness are, by definition, absent in patients with OME. However, children with fever resulting from other causes may continue to have fluid present in the middle ear from a prior episode of AOM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H22228262#H22228262\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Hearing loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever fluid fills the middle ear, there is conductive hearing impairment. The median loss is 25 dB, which is the equivalent of putting plugs in your ears. The infant may not be able to express the hearing loss, but it may be apparent to the parent. Older children and adults usually recognize the hearing impairment. OME is transient in most children and may never be recognized. However, some children may have OME with concomitant hearing impairment for weeks to months that is only recognized when the child presents for medical attention. Infants with prolonged duration of middle-ear effusion during the first three years of life may have decreased scores in tests of speech, language, and cognitive abilities at seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbances are reported most commonly by parents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/17\">",
"     17",
"    </a>",
"    ]. Vertigo is not a common complaint of OME but may occur. In the young child, vertigo or imbalance can be recognized by disequilibrium, falling, stumbling, or clumsiness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The older child with vertigo may describe a feeling of spinning or turning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most significant complication of OME is conductive hearing loss, as described above. If the tympanic membrane becomes severely retracted, forming a retraction pocket, a cholesteatoma can occur, either due to accumulation of squamous debris within the pocket with extension to the middle-ear space, or primarily within the middle-ear space. Cholesteatoma is the accumulation of desquamating epithelium or keratin within the middle ear, and in extreme cases, it may grow to envelop the ossicles and result in conductive hearing loss and destruction of the ossicular chain (",
"    <a class=\"graphic graphic_picture graphicRef66686 \" href=\"UTD.htm?13/14/13551\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link\">",
"     \"Cholesteatoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potential complication is tympanosclerosis, which is characterized by whitish plaques in the tympanic membrane; occasionally, the middle ear becomes involved, as well. Tympanosclerosis may be associated with frequent episodes of AOM and OME. In most children, the scarring of the tympanic membrane is of no functional importance, but in some, the deposits may envelop the ossicles and result in conductive hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;OME is defined as the presence of MEE in the absence of acute signs and symptoms of infection. The gold standard to make the diagnosis is pneumatic otoscopy. Tympanometry and acoustic reflectometry are used as adjuncts to support the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumatic otoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tympanic membrane in children with OME is usually gray or translucent (",
"    <a class=\"graphic graphic_picture graphicRef73735 \" href=\"UTD.htm?21/57/22431\">",
"     picture 2",
"    </a>",
"    ), and not erythematous, as occurs with acute inflammation. The tympanic membrane is usually in a neutral or retracted position. The fluid-filled middle ear prevents mobility of the tympanic membrane when positive pressure is applied with the bulb during pneumatic otoscopy; however, some movement may be apparent when negative pressure is applied initially to the tympanic membrane. Bulging or fullness of the tympanic membrane is a feature of AOM and is not a typical feature of OME. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Otoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumatic otoscopy is recommended as the primary diagnostic method in the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), and American Academy of Otolaryngology-Head and Neck Surgery (AAOHNS) clinical practice guideline for otitis media with effusion in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Compared with other diagnostic methods (eg, nonpneumatic otoscopy, tympanometry, acoustic reflectometry), pneumatic otoscopy had the best balance of sensitivity and specificity for validated observers using myringotomy as the gold standard (pooled sensitivity of 94 percent, 95% CI 91-96 percent; pooled specificity of 80 percent, 95% CI 75-86 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/23\">",
"     23",
"    </a>",
"    ]. The accuracy of pneumatic otoscopy in less experienced hands may be less than that in published reports because of varying levels of training and experience [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjunctive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanometry and acoustic reflectometry are available as handheld instruments for portability and ease of use. These tests may be employed as adjunctive techniques when the presence of middle-ear fluid is difficult to determine based upon otoscopic examination.",
"   </p>",
"   <p>",
"    Tympanometry measures the compliance of the tympanic membrane and middle ear and generally is performed as a confirmatory rather than a screening test; portable devices are available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. When fluid is present in the middle ear, the tympanogram is characterized by reduced height of the curve (ie, the middle ear has reduced compliance) or a flat curve without a peak (",
"    <a class=\"graphic graphic_figure graphicRef80293 \" href=\"UTD.htm?42/33/43550\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Acoustic reflectometry (AR) with spectral wave analysis measures the reflection of sound from the tympanic membrane. AR provides a measure of the difference in sound intensity from the incident and reflected sound waves around the frequency of maximal nullification. Acoustic reflectometry with spectral gradient analysis is available as a handheld instrument (EarCheck PRO Otitis Media Detector, Innovia Medical, Lenexa, KS). A consumer model is also available and may be of value for parents of children who have recurrent AOM or persistent OME.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    guideline recommends a hearing evaluation in children in whom OME has persisted for at least three months or in whom language delay, learning problems, or a significant hearing loss (&ge;21 dB) is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. The type of testing performed depends upon the age and cooperation of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Speech and language evaluation also should be conducted in children with OME for &ge;3 months' duration and in whom hearing loss (&ge;21 dB) is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     At-risk children",
"    </span>",
"    &nbsp;&mdash;&nbsp;At-risk children include those who have hearing loss independent of OME, suspected or diagnosed speech and language delay or disorder, autism spectrum disorders, craniofacial disorders, developmental delay, and uncorrectable visual impairment. In these children, a minimal amount of hearing loss may have a greater impact on speech and language, and earlier evaluation of hearing, speech, and language than for other children with OME is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion of otitis media with effusion is continued separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;OME resolves without medical intervention in the vast majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, some patients have OME that persists for weeks to months; these patients may have problems from the associated hearing loss. The goal of management is to eliminate the effusion, restore normal hearing, and when feasible prevent future episodes.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    clinical practice guideline serves as the basis for current management of patients with prolonged (&ge;3 months) OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. This guideline applies to all children between 2 months and 12 years of age, including those with developmental disabilities and underlying conditions that predispose to OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management options include watchful waiting, pharmacologic therapy, and surgery. Which strategy is undertaken, and when, depends upon the presence of or risk for speech, language, or learning problems and on the severity of accompanying hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     At-risk children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are at risk for speech, language, or learning problems require earlier intervention than other children with OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. This group includes children who have hearing loss independent of OME, suspected or diagnosed speech and language delay or disorder, autism spectrum disorders, craniofacial disorders, developmental delay, and uncorrectable visual impairment. The clinical practice guidelines for OME suggest early surgical referral (ie, within three months of onset) for such children. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Degree of hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, children who are not at risk for speech, language, or learning problems and whose OME persists for &ge;3 months should undergo hearing evaluation. The results of the hearing test determine, to some extent, the management strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with hearing loss &le;20 dB and without speech, language, or developmental problems can be managed with watchful waiting [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with hearing loss 21 to 39 dB can be managed with watchful waiting or referred for surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"       22",
"      </a>",
"      ]. We suggest such children be referred for surgical evaluation.",
"     </li>",
"     <li>",
"      Children with hearing loss &ge;40 dB should be referred for surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Watchful waiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    clinical practice guideline recommends that children who have OME and are not at risk for speech, language, or learning problems and whose associated hearing loss is &le;20 dB be managed with watchful waiting for three months from the onset of the effusion (or the diagnosis of effusion if the date of onset is not known) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. This recommendation is based upon the high likelihood of spontaneous resolution of OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evaluation and hearing test should be repeated every three to six months until the effusion has resolved or the child develops an indication for surgical referral. We recommend prompt surgical referral for diagnosed or suspected structural abnormalities of the tympanic membrane or middle ear or if the patient develops symptoms other than hearing loss (eg, pain, vertigo). We suggest surgical referral for hearing loss &ge;21 dB, bilateral OME for &ge;3 months, unilateral OME &ge;6 months, or cumulative duration of OME &ge;12 months. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Watchful waiting also is an option for children with mild conductive hearing loss (21 to 39 dB) whose parents prefer to avoid or postpone surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. During the observation period, mild conductive hearing loss can be addressed by speaking in close proximity to the child, facing the child and speaking clearly, repeating phrases when misunderstood, and providing preferential classroom seating [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/29\">",
"     29",
"    </a>",
"    ]. Repeat hearing tests should be performed in three to six months, as described in the paragraph above.",
"   </p>",
"   <p>",
"    A systematic review of the use of tympanostomy tubes (grommets) for hearing loss associated with OME supports a strategy of watchful waiting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/30\">",
"     30",
"    </a>",
"    ]. Although children who received tympanostomy tubes spent less time with effusion during the first postoperative year, improvements in hearing loss were diminished over time. In otherwise-healthy children, there were no proven effects on language development or cognition. This study is discussed in greater detail below. Another study, in which children (younger than three years) with persistent MEE were randomly assigned to prompt or delayed insertion of tympanostomy tubes, provides additional support for conservative management. Developmental outcomes were assessed at 3, 4, 6, and 9 to 11 years of age and were the same between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Tympanostomy tubes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pharmacologic therapies, including antibiotics, antihistamines, decongestants, and corticosteroids have been evaluated for the treatment of OME. Among these, only antibiotics have been shown to be beneficial, but the effect is small and short lived, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small improvement following a course of an antibiotic has been described in some studies, although the studies have differed in quality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/35\">",
"     35",
"    </a>",
"    ]. Two meta-analyses suggest improved clearance of the effusion within the first month after treatment but frequent relapses of MEE and no benefit beyond the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    clinical practice guideline offers the option of providing a single 10- to 14-day course of antibiotics (typically amoxicillin) in some circumstances (eg, when the parents or caregivers express a strong aversion to impending surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. We support offering this option to select patients with appropriate follow-up if a course of antibiotics is chosen. There is no known benefit for resolution of the middle-ear fluid from a longer course of antibiotics, and prolonged or repeated courses of antibiotics are not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Tympanostomy tubes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Antihistamines and decongestants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines and decongestants are not recommended for the treatment of OME in children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. In a systematic review of 16 randomized trials, treatment with antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decongestants neither reduced the duration of OME nor prevented complications (recurrent OME or acute otitis media) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/38\">",
"     38",
"    </a>",
"    ]. However, treatment with antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decongestants was associated with increased risk side effects (17 versus 6 percent among placebo recipients). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    clinical practice guideline recommends against administering corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic and topical nasal corticosteroids have been evaluated for efficacy in the management of OME. A systematic review summarized the existing data as favoring oral corticosteroids for the short- but not the long-term resolution of effusions and found no evidence of benefit with intranasal corticosteroids; neither oral nor topical corticosteroids improved hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/39\">",
"     39",
"    </a>",
"    ]. The reviewers noted there was considerable heterogeneity among the studies and that long-term hearing and speech development were not assessed.",
"   </p>",
"   <p>",
"    As a representative example, a randomized trial in 144 children between the ages of one and nine years with persisting effusion for at least two months compared four regimens: amoxicillin for 14 or 28 days, amoxicillin plus prednisolone for 14 days, and amoxicillin plus oral prednisolone for 14 days with an additional 14 days of amoxicillin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients receiving prednisolone were significantly more likely to be free of effusion at two weeks but not at four weeks, regardless of whether amoxicillin was continued for the extra 14 days. At four months, effusion had recurred in 68.4 percent of children receiving corticosteroids and 69.2 percent of those receiving antibiotics alone. This study supports the recommendation that corticosteroids provide only short-term benefits and should",
"    <strong>",
"     not",
"    </strong>",
"    be administered routinely in children with OME.",
"   </p>",
"   <p>",
"    Individual randomized trials of intranasal corticosteroids have had conflicting results, but most demonstrate no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    guidelines and the National Institute for Health and Clinical Excellence (NICE) guidelines recommend against the use of intranasal corticosteroids for the treatment of OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22,45\">",
"     22,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Autoinflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoinflation refers to the process of opening the eustachian tube by raising intranasal pressure (eg, by forced exhalation with closed mouth and nose, blowing up a balloon through each nostril, or using a purpose-manufactured nasal balloon) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Published studies of this intervention, none of which were blinded, have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/48-52\">",
"     48-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of six studies comparing any form of autoinflation to no autoinflation in patients with OME found improvement in the composite measure of tympanogram or audiometry at more than one month (relative risk of improvement 2.2, 95% CI 1.7-2.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/47\">",
"     47",
"    </a>",
"    ]. A systematic review of three studies of treatment of OME with a purpose-manufactured nasal balloon found that autoinflation improved MEE by tympanometric and audiometric criteria within two weeks to three months compared to no treatment (odds ratio 3.5, 95% CI 2.0-6.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No adverse effects were reported with autoinflation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, some children may find this technique difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/35,53\">",
"     35,53",
"    </a>",
"    ]. In one trial, 12 percent of children (3 to 12 years) were unable to use the balloon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoinflation with a purpose-manufactured nasal balloon is an alternative to watchful waiting for the older child who has continued problems with OME and is able to perform the technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of homeopathic remedies have been proposed for the treatment of AOM and OME. The few published studies of homeopathic remedies for middle ear infections have defects in study design, including small sample size, lack of randomization or blinding, and lack of validation of the diagnosis. In addition, there are no standardized homeopathic regimens for otitis media and no data on appropriate doses or schedules. The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    guideline makes no recommendations regarding complementary and alternative therapies for OME based upon this lack of evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]. We recommend against homeopathic remedies in the treatment of OME.",
"   </p>",
"   <p>",
"    Because the pathogenesis of OME is still obscure, it is possible that innovative therapies may be effective and also provide insight into the reasons for development of OME. A randomized trial of a nasal spray of bacterial suspensions was performed in 60 Swedish children with prolonged OME (median six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/54\">",
"     54",
"    </a>",
"    ]. The nasal sprays were prepared from Streptococcus sanguinis or Lactobacillus rhamnosus or placebo suspended in saline. The suspensions were administered as two puffs of spray per nostril twice daily for 10 days. A modest benefit was seen in each of the bacterial groups compared to placebo. No adverse effects were identified. The results are preliminary but worthy of further investigation as a safe and easily administered therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otolaryngologists (ORL) should be consulted about children with recurrent and severe AOM or persistent OME, those who may require myringotomy and placement of ventilating tubes, and those with structural abnormalities of the tympanic membrane or middle ear. The final decision regarding surgery should involve the ORL, parent(s) or caregiver(s), and the primary care provider.",
"   </p>",
"   <p>",
"    When making a referral, the primary care provider should provide the ORL specialist with the following information [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The duration and laterality of the effusion",
"     </li>",
"     <li>",
"      Results of hearing tests or tympanometry",
"     </li>",
"     <li>",
"      Child's history of AOM",
"     </li>",
"     <li>",
"      Whether the child has suspected or diagnosed speech and language problems, or any risks for hearing, language, or learning problems",
"     </li>",
"     <li>",
"      Specific reason for referral (eg, evaluation, surgery)",
"     </li>",
"     <li>",
"      The primary care clinician will usually be responsible for the follow-up care of the patient in consultation with the ORL specialist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tympanostomy tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most successful technique for ridding the middle ear of fluid, restoring the health of the middle-ear mucosa, improving hearing loss, and maintaining an air-filled middle-ear space is myringotomy and placement of tympanostomy tubes (also called ventilation tubes or grommets).",
"   </p>",
"   <p>",
"    A systematic review evaluated the use of tympanostomy tubes for hearing loss associated with OME compared with myringotomy or nonsurgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/30\">",
"     30",
"    </a>",
"    ]. Although children who received tympanostomy tubes spent less time with effusion during the first postoperative year, improvements in hearing loss diminished over time, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children treated with tympanostomy tubes spent 32 percent (95% CI 17-48 percent) less time with MEE during the first year of follow-up.",
"     </li>",
"     <li>",
"      Hearing levels were improved in children treated with tympanostomy tubes (mean hearing levels in children treated with tympanostomy tubes improved by 10 dB (95% CI 5-16 dB) after the four to six months and by 6 dB (95% CI 2-10 dB) after 12 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are inconsistent with the parental and clinical observation that the effects of tympanostomy tubes are beneficial and often dramatic, with a rapid increase in speech following insertion, as well as improvements in the quality of life for these children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    guideline provides the following indications for tympanostomy tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with hearing loss &ge;40 dB.",
"     </li>",
"     <li>",
"      Children who have structural damage to the tympanic membrane or middle ear (prompt referral is recommended).",
"     </li>",
"     <li>",
"      Children who have OME of &ge;4 months' duration with persistent hearing loss (&ge;21 dB) or other signs or symptoms.",
"     </li>",
"     <li>",
"      Children with recurrent or persistent OME who are at risk of speech, language, or learning problems, regardless of hearing status (early referral [within three months] is recommended).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest broader indications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/26,55\">",
"     26,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OME that has persisted for three or more months if bilateral and six months if unilateral.",
"     </li>",
"     <li>",
"      Recurrent episodes of OME that may not meet the above criteria for chronicity but have an unacceptable cumulative duration, such as being present for 6 of the last 12 months.",
"     </li>",
"     <li>",
"      Signs of eustachian tube dysfunction unresponsive to medical therapy even without current effusion (eg, fluctuating hearing loss, disequilibrium or vertigo, tinnitus, autophony [vibration and reverberation of the patient's voice], severe retraction pocket of the tympanic membrane, intermittent pain).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some evidence to suggest that surgical intervention may improve the quality of life of children with recurrent AOM",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    OME. Investigators used a questionnaire to follow 123 children who had had bilateral myringotomy and placement of tympanostomy tubes with or without adenoidectomy. They noted a 75 and 60 percent decrease in total ear symptom scores, respectively, at one and six months, as well as a decrease in parental worry about ear problems at both time points [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of tympanostomy tubes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes\", section on 'Complications and sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Adenoidectomy and tonsillectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    guideline states that adenoidectomy should not be performed as the initial procedure in children with persistent OME without a distinct indication for the adenoidectomy other than OME (eg, nasal obstruction, chronic adenoiditis, chronic sinusitis). Although there appears to be some benefit to adenoidectomy in children older than four years with OME, the additional surgical and anesthetic risks outweigh the short-term benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/57\">",
"     57",
"    </a>",
"    ]. The limited data regarding adenoidectomy in children younger than four years of age prevent a definitive recommendation for this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/26,55\">",
"     26,55",
"    </a>",
"    ]. In a randomized trial comparing tympanostomy tube insertion with or without adenoidectomy in children (12 to 48 months of age) with recurrent or persistent otitis media, adenoidectomy was associated with increased carriage of pneumococci, raising the question of what role the adenoids play in host defense [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/58\">",
"     58",
"    </a>",
"    ]. This study was conducted before routine use of the pneumococcal conjugate vaccine in Finland, and it is not clear what the implications might be for immunized children.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     AAP/AAFP/AAOHNS",
"    </span>",
"    guideline recommends adenoidectomy (and concurrent myringotomy) when repeat surgery for OME is necessary (eg, when effusion recurs after tympanostomy tubes have fallen out or are removed) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ], because adenoidectomy reduces the need for future operations for OME [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/57,59,60\">",
"     57,59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link\">",
"     \"Tonsillectomy and adenoidectomy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tonsillectomy does not appear to improve the outcome for OME and is generally not advised unless there are other indications for removal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/9/20626?source=see_link\">",
"       \"Patient information: Ear tubes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Otitis media with effusion (OME) is defined as the presence of middle ear effusion (MEE) in the absence of acute signs and symptoms of infection. OME may arise after a recognized or unrecognized episode of acute otitis media. MEE is accompanied by conductive hearing loss (median 25 dB). Prolonged hearing impairment during the first years of life may affect development of speech and language. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical signs of acute illness are, by definition, absent in patients with OME. Associated complaints may include sleep disturbance (most common), hearing loss, or vertigo. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of OME is usually made with pneumatic otoscopy that demonstrates reduced mobility or immobility of the tympanic membrane with positive pressure in the absence of acute signs of inflammation. Tympanometry and reflectometry are adjunctive diagnostic tests. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hearing evaluation should be performed at the time of diagnosis of OME in children in whom language delay, learning problems, or a significant hearing loss is suspected. Hearing evaluation also should be performed in children without such problems in whom OME has persisted for at least three months. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"       \"Evaluation of hearing impairment in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Speech and language screening evaluation should be conducted in children with OME for &ge;3 months' duration and hearing loss (&ge;21 dB). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of OME is one of spontaneous resolution, which can happen within days, but more often takes up to 12 weeks. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of children with OME depends upon whether the child has structural damage to the tympanic membrane or middle ear or speech, language, or learning problems, and on the severity of the accompanying hearing loss. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend prompt surgical referral for children who have structural damage to the tympanic membrane or middle ear (eg, retraction pocket, cholesteatoma, or tympanosclerosis) and children with hearing loss &ge;40 dB (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical referral within three months for children with OME who suffer from hearing loss independent of OME, suspected or diagnosed speech or language disorder, developmental delay, and uncorrectable visual impairment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical referral for children without developmental, language, or visual problems who have hearing loss &ge;21 dB, bilateral OME for &ge;3 months, unilateral OME &ge;6 months, or cumulative duration of OME &ge;12 months (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend watchful waiting for children without speech, language, or developmental problems and with hearing loss &le;20 dB (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Children who are managed with watchful waiting should be reevaluated (with hearing testing) every three to six months until the effusion has resolved or the child develops an indication for surgical referral. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Watchful waiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using antihistamines, decongestants, or corticosteroids routinely in the management of OME in children (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Antihistamines and decongestants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/1\">",
"      Teele DW, Klein JO, Chase C, et al. Otitis media in infancy and intellectual ability, school achievement, speech, and language at age 7 years. Greater Boston Otitis Media Study Group. J Infect Dis 1990; 162:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/2\">",
"      Birch L, Elbr&oslash;nd O. Daily impedance audiometric screening of children in a day-care institution. Changes through one month. Scand Audiol 1985; 14:5.",
"     </a>",
"    </li>",
"    <li>",
"     Stool, SE, Berg, AO, Berman, S, et al. Otitis media with effusion in young children. Clinical Practice Guideline, Number 12. AHCPR publication No. 94-0622. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/4\">",
"      Depreux FF, Darrow K, Conner DA, et al. Eya4-deficient mice are a model for heritable otitis media. J Clin Invest 2008; 118:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/5\">",
"      Lazaridis E, Saunders JC. Can you hear me now? A genetic model of otitis media with effusion. J Clin Invest 2008; 118:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/6\">",
"      Ehrlich GD, Veeh R, Wang X, et al. Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA 2002; 287:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/7\">",
"      Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006; 296:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/8\">",
"      Alles R, Parikh A, Hawk L, et al. The prevalence of atopic disorders in children with chronic otitis media with effusion. Pediatr Allergy Immunol 2001; 12:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/9\">",
"      Hurst DS, Venge P. The impact of atopy on neutrophil activity in middle ear effusion from children and adults with chronic otitis media. Arch Otolaryngol Head Neck Surg 2002; 128:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/10\">",
"      Lieu JE, Muthappan PG, Uppaluri R. Association of reflux with otitis media in children. Otolaryngol Head Neck Surg 2005; 133:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/11\">",
"      Antonelli PJ, Lloyd KM, Lee JC. Gastric reflux is uncommon in acute post-tympanostomy otorrhea. Otolaryngol Head Neck Surg 2005; 132:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/12\">",
"      Crapko M, Kerschner JE, Syring M, Johnston N. Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope 2007; 117:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/13\">",
"      O'Reilly RC, He Z, Bloedon E, et al. The role of extraesophageal reflux in otitis media in infants and children. Laryngoscope 2008; 118:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/14\">",
"      Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992; 11:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/15\">",
"      Poetker DM, Lindstrom DR, Edmiston CE, et al. Microbiology of middle ear effusions from 292 patients undergoing tympanostomy tube placement for middle ear disease. Int J Pediatr Otorhinolaryngol 2005; 69:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/16\">",
"      Brook I, Yocum P, Shah K, et al. Microbiology of serous otitis media in children: correlation with age and length of effusion. Ann Otol Rhinol Laryngol 2001; 110:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/17\">",
"      Rosenfeld RM, Goldsmith AJ, Tetlus L, Balzano A. Quality of life for children with otitis media. Arch Otolaryngol Head Neck Surg 1997; 123:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/18\">",
"      Casselbrant ML, Furman JM, Rubenstein E, Mandel EM. Effect of otitis media on the vestibular system in children. Ann Otol Rhinol Laryngol 1995; 104:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/19\">",
"      Orlin MN, Effgen SK, Handler SD. Effect of otitis media with effusion on gross motor ability in preschool-aged children: preliminary findings. Pediatrics 1997; 99:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/20\">",
"      Golz A, Angel-Yeger B, Parush S. Evaluation of balance disturbances in children with middle ear effusion. Int J Pediatr Otorhinolaryngol 1998; 43:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/21\">",
"      Casselbrant ML, Redfern MS, Furman JM, et al. Visual-induced postural sway in children with and without otitis media. Ann Otol Rhinol Laryngol 1998; 107:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/22\">",
"      American Academy of Family Physicians, American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Pediatrics Subcommittee on Otitis Media With Effusion. Otitis media with effusion. Pediatrics 2004; 113:1412.",
"     </a>",
"    </li>",
"    <li>",
"     Shekelle, P Takata, G, Chan, LS, et al. Diagnosis, natural history, and late effects of otitis media with effusion. Evidence report/ Technology assessment No. 55. AHRQ Publication No. 03-E023. Agency for Healthcare Research and Quality, Rockville, MD, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/24\">",
"      Pichichero ME, Poole MD. Assessing diagnostic accuracy and tympanocentesis skills in the management of otitis media. Arch Pediatr Adolesc Med 2001; 155:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/25\">",
"      Steinbach WJ, Sectish TC. Pediatric resident training in the diagnosis and treatment of acute otitis media. Pediatrics 2002; 109:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/26\">",
"      Bluestone CD, Klein JO. Clinical practice guideline on otitis media with effusion in young children: strengths and weaknesses. Otolaryngol Head Neck Surg 1995; 112:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/27\">",
"      Teele DW, Klein JO, Rosner BA. Epidemiology of otitis media in children. Ann Otol Rhinol Laryngol Suppl 1980; 89:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/28\">",
"      Rosenfeld RM, Kay D. Natural history of untreated otitis media. Laryngoscope 2003; 113:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/29\">",
"      Roberts JE, Rosenfeld RM, Zeisel SA. Otitis media and speech and language: a meta-analysis of prospective studies. Pediatrics 2004; 113:e238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/30\">",
"      Browning GG, Rovers MM, Williamson I, et al. Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev 2010; :CD001801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/31\">",
"      Paradise JL, Feldman HM, Campbell TF, et al. Effect of early or delayed insertion of tympanostomy tubes for persistent otitis media on developmental outcomes at the age of three years. N Engl J Med 2001; 344:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/32\">",
"      Paradise JL, Dollaghan CA, Campbell TF, et al. Otitis media and tympanostomy tube insertion during the first three years of life: developmental outcomes at the age of four years. Pediatrics 2003; 112:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/33\">",
"      Paradise JL, Campbell TF, Dollaghan CA, et al. Developmental outcomes after early or delayed insertion of tympanostomy tubes. N Engl J Med 2005; 353:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/34\">",
"      Paradise JL, Feldman HM, Campbell TF, et al. Tympanostomy tubes and developmental outcomes at 9 to 11 years of age. N Engl J Med 2007; 356:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/35\">",
"      Williamson I. Otitis media with effusion. Clin Evid 2004; :764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/36\">",
"      Rosenfeld RM, Post JC. Meta-analysis of antibiotics for the treatment of otitis media with effusion. Otolaryngol Head Neck Surg 1992; 106:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/37\">",
"      Williams RL, Chalmers TC, Stange KC, et al. Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion. A meta-analytic attempt to resolve the brouhaha. JAMA 1993; 270:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/38\">",
"      Griffin G, Flynn CA. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database Syst Rev 2011; :CD003423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/39\">",
"      Simpson SA, Lewis R, van der Voort J, Butler CC. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev 2011; :CD001935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/40\">",
"      Mandel EM, Casselbrant ML, Rockette HE, et al. Systemic steroid for chronic otitis media with effusion in children. Pediatrics 2002; 110:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/41\">",
"      Tracy JM, Demain JG, Hoffman KM, Goetz DW. Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Ann Allergy Asthma Immunol 1998; 80:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/42\">",
"      Shapiro GG, Bierman CW, Furukawa CT, et al. Treatment of persistent eustachian tube dysfunction in children with aerosolized nasal dexamethasone phosphate versus placebo. Ann Allergy 1982; 49:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/43\">",
"      Cengel S, Akyol MU. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. Int J Pediatr Otorhinolaryngol 2006; 70:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/44\">",
"      Williamson I, Benge S, Barton S, et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ 2009; 339:b4984.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Surgical management of otitis media with effusion in children. 2008. www.nice.org.uk/nicemedia/pdf/CG60NICEguideline.pdf (Accessed on November 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/46\">",
"      Reidpath DD, Glasziou PP, Del Mar C. Systematic review of autoinflation for treatment of glue ear in children. BMJ 1999; 318:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/47\">",
"      Perera R, Haynes J, Glasziou P, Heneghan CJ. Autoinflation for hearing loss associated with otitis media with effusion. Cochrane Database Syst Rev 2006; :CD006285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/48\">",
"      Chan KH, Bluestone CD. Lack of efficacy of middle-ear inflation: treatment of otitis media with effusion in children. Otolaryngol Head Neck Surg 1989; 100:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/49\">",
"      Fraser JG, Mehta M, Fraser PA. The medical treatment of secretory otitis media. A clinical trial of three commonly used regimes. J Laryngol Otol 1977; 91:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/50\">",
"      Brooker DS, McNeice A. Autoinflation in the treatment of glue ear in children. Clin Otolaryngol Allied Sci 1992; 17:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/51\">",
"      Blanshard JD, Maw AR, Bawden R. Conservative treatment of otitis media with effusion by autoinflation of the middle ear. Clin Otolaryngol Allied Sci 1993; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/52\">",
"      Stangerup SE, Sederberg-Olsen J, Balle V. Autoinflation as a treatment of secretory otitis media. A randomized controlled study. Arch Otolaryngol Head Neck Surg 1992; 118:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/53\">",
"      Haggard M. Commentary:plausible candidates for treatment of glue ear-is one issue really three? BMJ 1999; 318:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/54\">",
"      Skovbjerg S, Roos K, Holm SE, et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child 2009; 94:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/55\">",
"      Bluestone CD. Role of surgery for otitis media in the era of resistant bacteria. Pediatr Infect Dis J 1998; 17:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/56\">",
"      Richards M, Giannoni C. Quality-of-life outcomes after surgical intervention for otitis media. Arch Otolaryngol Head Neck Surg 2002; 128:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/57\">",
"      Gates GA, Avery CA, Prihoda TJ, Cooper JC Jr. Effectiveness of adenoidectomy and tympanostomy tubes in the treatment of chronic otitis media with effusion. N Engl J Med 1987; 317:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/58\">",
"      Mattila PS, Hammar&eacute;n-Malmi S, Saxen H, et al. Adenoidectomy and nasopharyngeal carriage of Streptococcus pneumoniae in young children. Arch Dis Child 2010; 95:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/59\">",
"      Paradise JL, Bluestone CD, Rogers KD, et al. Efficacy of adenoidectomy for recurrent otitis media in children previously treated with tympanostomy-tube placement. Results of parallel randomized and nonrandomized trials. JAMA 1990; 263:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22153/abstract/60\">",
"      Maw AR. Chronic otitis media with effusion (glue ear) and adenotonsillectomy: prospective randomised controlled study. Br Med J (Clin Res Ed) 1983; 287:1586.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5966 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22153=[""].join("\n");
var outline_f21_40_22153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumatic otoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjunctive tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      At-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      At-risk children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Degree of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Watchful waiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Antihistamines and decongestants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Autoinflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Adenoidectomy and tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5966|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/33/43550\" title=\"figure 1\">",
"      Tympanogram in OME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5966|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/14/13551\" title=\"picture 1\">",
"      Cholesteatoma of the middle ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/57/22431\" title=\"picture 2\">",
"      Chronic OM with effusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3978?source=related_link\">",
"      Overview of tympanostomy tube placement and medical care of children with tympanostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/9/20626?source=related_link\">",
"      Patient information: Ear tubes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22154="Complications of renal transplantation in children";
var content_f21_40_22154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of renal transplantation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22154/contributors\">",
"     Ruth A McDonald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22154/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/40/22154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/40/22154/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/40/22154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the estimated glomerular filtration rate declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 (stage 4 chronic kidney disease), it is time to start preparing the child and the family for renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there have been many advances in conservative renal replacement therapy, renal transplantation is the best treatment for children with end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/2\">",
"     2",
"    </a>",
"    ]. This was shown in a study from Australia and New Zealand, in which the risk for death was more than four times higher in children with ESRD treated with dialysis rather than renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/2\">",
"     2",
"    </a>",
"    ]. Improvements in the care of young patients and advances in immunosuppressive therapy have also increased renal allograft and patient survival. Particularly, reduction in the frequency and severity of acute rejection has enhanced allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of the complications of renal transplantation in children. Some complications of renal transplantation are unique to children, while others are observed in all transplant recipients. Additional issues concerning transplantation in children and issues in renal transplantation common to both children and adults are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=see_link\">",
"     \"General principles of kidney transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link\">",
"     \"Outcomes of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GRAFT DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of renal allograft dysfunction vary with the time after transplantation. These time periods are usually classified as immediate (zero to one week postsurgery), early (1 to 12 weeks postsurgery), late acute (after three months), and late chronic (years). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of delayed graft function (immediate renal failure persisting after transplantation) include postischemic acute kidney injury, vascular thrombosis of the renal artery or vein, urologic complications (ie, urinary leak or obstruction), and rarely, hyperacute rejection.",
"     </li>",
"     <li>",
"      Among patients with initial graft function who develop early renal insufficiency (ie, 1 to 12 weeks posttransplantation), the major causes of graft dysfunction are acute allograft rejection, calcineurin inhibitor toxicity, urinary obstruction, infection, hypovolemia, and recurrent disease.",
"     </li>",
"     <li>",
"      Allograft dysfunction that acutely develops more than three months after transplantation is most commonly due to acute allograft rejection, calcineurin inhibitor toxicity, urinary obstruction, hypovolemia, pyelonephritis, and recurrent or de novo renal disease.",
"     </li>",
"     <li>",
"      Slowly progressive renal disease that occurs over a period of years after renal transplantation most commonly results from chronic allograft injury, calcineurin inhibitor nephrotoxicity, hypertensive nephrosclerosis, viral infections, and recurrent or de novo renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Delayed graft function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal failure persisting after transplantation is called delayed graft function (DGF). The definition of DGF varies in different studies but generally refers to oliguria or the requirement for dialysis in the first week posttransplantation. Previously, patients with DGF have had a 15 to 25 percent lower graft survival rate than those without DGF. An increasing number of grafts are being recovered from donation after cardiac death (DCD). Although DCD transplants have a higher incidence of DGF, the short-term survival rates of these grafts are similar to those without DGF [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major causes of DGF in children are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postischemic acute kidney injury is the most common cause of DGF",
"     </li>",
"     <li>",
"      Thrombosis or embolization of the renal artery or vein",
"     </li>",
"     <li>",
"      Accelerated rejection superimposed on ischemic ATN",
"     </li>",
"     <li>",
"      Urologic abnormalities (ie, urinary leak or hematoma)",
"     </li>",
"     <li>",
"      Hyperacute rejection (generally preventable)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors may be responsible for postischemic acute kidney injury. These include the age and condition of the donor, specific recovery procedure, technique of organ preservation, adequacy of volume replacement during and after surgery, and the cold and warm ischemia times. Tubular damage may be aggravated by the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . There is evidence that the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    in combination with either cyclosporine or tacrolimus prolongs DGF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Vascular thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular thrombosis of the renal artery or vein is the third most common cause of graft failure in children receiving renal transplants. The main risk for thrombosis is an extremely young donor or recipient. Other risk factors include hypercoagulability (such as that due to chronic nephrotic syndrome) and venous malformation in the recipient, pretransplant peritoneal dialysis, a hypotensive episode during or after surgery, the presence of multiple arteries, and bench surgery of graft vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/5\">",
"     5",
"    </a>",
"    ]. Although vascular thrombosis is usually observed within the first few days following transplantation, it can be seen as late as three weeks post-transplant.",
"   </p>",
"   <p>",
"    The use of interleukin-2 receptor antagonists may be associated with a decreased risk of graft thrombosis. This was shown in a retrospective study of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) database of transplant patients between 1998 and 2004 in which the incidence of thrombosis was significantly lower among those who received such antibodies (1.07 versus 2.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other measures that may reduce the incidence of vascular thrombosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful hemodynamic monitoring of central venous pressure to ensure adequate allograft perfusion.",
"     </li>",
"     <li>",
"      Consideration of screening for inherited and acquired thrombophilic risk factors, especially if there is a family history or previous episode of thrombosis. Screening is currently available for protein C, S or antithrombin III deficiency, factor V Leiden, prothrombin gene mutations, and the presence of antiphospholipid antibodies. Prophylactic therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      , low-molecular-weight heparin,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      to prevent thrombosis for those with an increased risk of thrombophilia has been successful in preventing graft loss [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=see_link\">",
"       \"Screening for inherited thrombophilia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Correction of vascular depletion related to nephrotic [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Urologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early posttransplant urological complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary leak due to ureteral necrosis, bladder injury, or obstruction.",
"     </li>",
"     <li>",
"      Urinary tract obstruction, most often due to clots in the urinary tract, postoperative edema, or surgical complication. It is detected as hydronephrosis by renal ultrasonography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although ureteral stents have been proposed as a measure to reduce these complications, their efficacy remains uncertain. In one trial, the use of a ureteral stent at renal transplantation significantly decreased urinary leak and obstruction with a reduction in overall medical costs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, a retrospective study found no difference in graft survival and the risk of urinary leakage and ureteral stenosis between patients who had stent placement from those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/12\">",
"     12",
"    </a>",
"    ]. In this report, stent placement also resulted in additional costs. Both studies demonstrated an increased risk of urinary tract infections with stent placement, especially if the stent remained in place beyond 30 days after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At our institution, stents are used in recipients who have bladder abnormalities with increased risk of urinary retention or high pressure, and when the transplant surgeon has concerns about the donor ureter. Our policy is to remove stents before the fourth week posttransplant. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Surgical sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperacute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperacute rejection occurring within the first minutes following transplantation results from preformed host anti-HLA antibodies that bind to vascular endothelial cells of the graft, resulting in activation of the complement cascade and endothelial injury. Neutrophils, macrophages, and platelets are attracted to the antibody binding site and cause further cellular damage. Platelet aggregation on the damaged endothelium leads to fibrin deposition and vascular thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/13\">",
"     13",
"    </a>",
"    ]. There are also reports of hyperacute rejection associated with anti-endothelial antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/14\">",
"     14",
"    </a>",
"    ], which are not detected using standard crossmatch methods using donor lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal allograft rejection is a frequent complication of pediatric renal recipients, which may occur several days, weeks, or months after transplantation. It is defined as an acute deterioration in allograft function, generally detected by an elevation in the serum creatinine level, which is associated with specific pathologic changes in the graft obtained via an allograft biopsy. The two principal histologic forms of rejection are acute cellular rejection and acute antibody-mediated rejection, which are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with renal transplants, the rate of acute rejection has decreased over the past 20 years. A report from NAPRTCS showed that the probability of first rejection in recipients of living donors during the first year had decreased from 54 to 9 percent between the two periods of 1987 to 1990 and 2003 to 2007. Similarly, a decrease was also seen in recipients of deceased donors from 69 to 18 percent between the same two time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"     3",
"    </a>",
"    ]. This decrease in the incidence of acute rejection appears to be due to the introduction of newer immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/15\">",
"     15",
"    </a>",
"    ]. Based upon the NAPRTCS data, hospitalization within the first 24 months following transplantation is more frequently caused by posttransplant infections than acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic signs of acute rejection, such as fever and graft tenderness, are observed less commonly with current immunosuppressive regimens. With these newer regimens, acute rejection episodes are often only detected by a rise in the serum concentration of creatinine.",
"   </p>",
"   <p>",
"    Among stable pediatric allograft recipients, the following strategy relating to the timing of serum creatinine concentration measurement is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Daily measurement during the first two weeks",
"     </li>",
"     <li>",
"      Twice to three times a week two to four weeks after transplantation",
"     </li>",
"     <li>",
"      Twice per week during the second month",
"     </li>",
"     <li>",
"      Weekly from the third to fourth month",
"     </li>",
"     <li>",
"      Twice a month from the fifth to eight months",
"     </li>",
"     <li>",
"      Monthly after the eighth month posttransplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute rejection is confirmed histologically via renal biopsy, a technique that can be performed with minimal risk in children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In the case of a small pediatric recipient of an adult-sized kidney, rejection may be present with no or only a small elevation in serum creatinine. In this setting, renal biopsy may be considered earlier when the results of the serum creatinine levels are equivocal.",
"   </p>",
"   <p>",
"    There is ongoing debate on the role of protocol biopsy in children to detect subclinical rejection, assess response to therapy for rejection, and surveillance for chronic allograft nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It remains to be demonstrated whether graft survival is improved by detecting these histological changes as suggested by results in adult patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following conditions may also present with an elevation in serum creatinine and need to be distinguished from acute rejection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary tract obstruction (generally ureteral obstruction) is differentiated from acute rejection by an ultrasound finding of hydronephrosis",
"     </li>",
"     <li>",
"      Calcineurin inhibitor nephrotoxicity is differentiated from acute rejection by renal biopsy",
"     </li>",
"     <li>",
"      Cytomegalovirus (CMV) and BK virus may cause graft dysfunction (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Viral infections'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link&amp;anchor=H35#H35\">",
"       \"Cytomegalovirus infection in renal transplant recipients\", section on 'CMV-induced renal disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=see_link\">",
"       \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Renal artery stenosis is an uncommon complication and is differentiated from acute rejection by imaging studies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H16699485#H16699485\">",
"       \"Establishing the diagnosis of renovascular hypertension\", section on 'Diagnostic test options'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyelonephritis may occur, especially in children with abnormal urinary tracts, and may present with fever, abdominal pain and decreased graft function",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic allograft injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to adults, the most common reported cause of graft loss after the first year among transplant recipients in children is chronic allograft injury (also known as chronic allograft nephropathy). This is a poorly understood disorder, and the etiology remains unknown. The revised 2005 Banff classification system renamed chronic allograft nephropathy to \"interstitial fibrosis and tubular atrophy, without evidence of any specific etiology\" because the terminology chronic allograft nephropathy was thought to discourage attempts to elucidate the underlying pathogenesis of this entity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic renal allograft nephropathy\", section on 'Banff grading system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the clinical diagnosis is suggested by the gradual deterioration of graft function as manifested by a slowly rising",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    creatinine concentration, increasing proteinuria (occasionally causing nephrotic range proteinuria), and worsening hypertension. It occurs at least three months post-transplant in the absence of acute rejection, drug toxicity (principally calcineurin inhibitors), or other nephrologic diseases.",
"   </p>",
"   <p>",
"    In a pediatric case series of 289 renal allografts, the risk factors for chronic allograft injury included at least one previous episode of acute rejection and the administration of low doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/21\">",
"     21",
"    </a>",
"    ]. Renal histology of biopsy samples reveals vascular proliferation of smooth-muscle cells, interstitial fibrosis, tubular atrophy, and glomerular sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple immunologic and nonimmunologic factors appear to contribute to the pathogenesis of this entity and are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link&amp;anchor=H10#H10\">",
"     \"Chronic renal allograft nephropathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitor toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following renal transplantation, calcineurin inhibitor (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) nephrotoxicity (CIN) may occur acutely and is largely reversible after reducing the dose, or as chronic progressive renal disease that is usually irreversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    De novo posttransplant thrombotic microangiopathy (TMA) may be associated with the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Although it can be difficult to treat, in some cases, withdrawing the offending agent may lead to resolution of TMA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12053?source=see_link&amp;anchor=H5#H5\">",
"     \"TTP-HUS: Recurrence after transplantation\", section on 'De novo HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonadherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonadherence with immunosuppressive medications is an important contributing factor for graft failure. The reported incidence of pediatric graft failure due to nonadherence ranges between 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Nonadherence correlates with poor outcome in patients with renal transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have shown a high incidence of nonadherence particularly among adolescents and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. A meta-analysis of medical regimen adherence in pediatric solid organ transplantation found that nonadherence to clinic appointments and tests was most prevalent, at 12.9 cases per 100 patients per year (PPY), followed by nonadherence to immunosuppression at 6",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    PPY [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/35\">",
"     35",
"    </a>",
"    ]. Poorer adherence was more likely in older age patients, and those with a worse psychological status and family dysfunction.",
"   </p>",
"   <p>",
"    Educational and counseling programs can improve medical regimen adherence that have the potential to improve graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECURRENCE OF PRIMARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most pediatric series, recurrence of primary disease is responsible for renal allograft failure in 5 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3,37,38\">",
"     3,37,38",
"    </a>",
"    ]. In the NAPRTCS database, the overall graft failure rate due to recurrent disease is about 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"     3",
"    </a>",
"    ]. Among the glomerular diseases that may recur in the graft, the most frequent is focal segmental glomerular sclerosis (FSGS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Focal segmental glomerulosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid-resistant idiopathic nephrotic syndrome due to primary FSGS accounts for 10 percent of cases of end-stage renal disease (ESRD) in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"     3",
"    </a>",
"    ]. The overall risk of recurrence of nephrotic syndrome after transplantation is estimated to be about 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/40\">",
"     40",
"    </a>",
"    ]. FSGS is the most frequent cause of graft loss due to recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of recurrence with FSGS is greater in children than adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, recurrence occurred in 8 of 16 children compared with 3 of 27 adults [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study reported an even higher recurrence rate in pediatric than adult patients (86 versus 35 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, recurrence is more frequent when the disease begins after the age of six years and there is a rapid progression to ESRD. In most series, the disease recurs in one-half of patients when the duration of disease has been shorter than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The histopathologic pattern observed in the first biopsy of the original disease is also an important predictive factor of disease recurrence. As an example, recurrence occurs in 50 to 80 percent of patients in whom the initial biopsy reveals diffuse mesangial proliferation (suggestive of more rapidly progressive disease), but in only 25 percent of patients with minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]. Patients with FSGS due to mutations in genes encoding podocyte proteins appear to have a lower risk of recurring disease after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of FSGS enhances the risk of allograft loss and is associated with an increased incidence of delayed graft function and acute rejection. Recurrence most often occurs within the first few days after transplantation. In patients with a first graft lost to recurrent disease, the recurrence rate is approximately 80 percent in a subsequent graft.",
"   </p>",
"   <p>",
"    Treatment remains controversial and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=see_link&amp;anchor=H15#H15\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Membranoproliferative glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranoproliferative glomerulonephritis (MPGN), which has three histologic forms, frequently recurs in the transplanted kidney. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, MPGN type I is the primary diagnosis in about 2 percent of pediatric kidney transplants [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"       3",
"      </a>",
"      ], and the rate of recurrence (about 20 to 30 percent) appears to be higher than that reported in adult patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Based upon the NAPRTCS database, MPGN type II was less common than MPGN type I as a primary diagnosis (0.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"       3",
"      </a>",
"      ], and the rate of recurrent disease was about 45 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/47\">",
"       47",
"      </a>",
"      ]. In this cohort of patients, 15 percent of graft failure was directly due to disease recurrence.",
"     </li>",
"     <li>",
"      MPGN III is a rare primary cause of ESRD in children, and there are no accurate data on its recurrence rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with both recurrent MPGN I and II disease, no successful therapeutic intervention has been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with hemolytic uremic syndrome (HUS), the risk of posttransplant recurrent disease varies depending upon the underlying cause of the primary disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with Shiga-like toxin associated or typical HUS generally caused by infection with Shiga-toxin producing Escherichia coli, the risk of posttransplant recurrence is less than 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=see_link&amp;anchor=H21#H21\">",
"       \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Recurrence after renal transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, the recurrence risk in non-Shiga-like associated (atypical) HUS is higher, especially in those with genetic causes of HUS [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. In particular, some mutations that result in dysregulation of the complement system are associated with a 50 percent recurrence rate, and graft failure occurs in 90 percent with those with recurrent disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link&amp;anchor=H7#H7\">",
"       \"Atypical hemolytic uremic syndrome in children\", section on 'Genetic forms of HUS'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Primary hyperoxaluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with primary hyperoxaluria, recurrence of oxalate deposits in the graft is constant, leading most commonly to graft failure. In children, the best approach to prevent systemic oxalosis is combined liver and kidney transplantation or chronic pyridoxine treatment in the sub-group of patients that are pyridoxine-responsive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/50\">",
"     50",
"    </a>",
"    ]. Although most of the experience has been with simultaneous",
"    <span class=\"nowrap\">",
"     liver/kidney",
"    </span>",
"    transplant when the patient has ESRD, there also has been reported success with preemptive liver transplant before the development of ESRD, thus delaying or avoiding the need for kidney transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link&amp;anchor=H6#H6\">",
"     \"Primary hyperoxaluria\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the following primary renal disorders, the recurrence rate is not clinically significant or unknown:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranous nephropathy is a rare cause of ESRD in children, and its recurrence rate is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with IgA nephropathy and Henoch-Sch&ouml;nlein purpura (IgA vasculitis) nephritis, the recurrence of IgA deposits in the graft is very common, but clinically relevant disease is infrequent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39367?source=see_link\">",
"       \"IgA nephropathy: Recurrence after transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lupus nephritis is the primary cause of ESRD in 3 percent of children undergoing renal transplantation in North America [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"       3",
"      </a>",
"      ]. However, recurrence of lupus nephritis in the transplanted kidney is rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=see_link\">",
"       \"End-stage renal disease due to lupus nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with Wilms tumor, the risk of recurrence or metastasis is negligible after two years of complete remission [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/51\">",
"       51",
"      </a>",
"      ]. Renal transplantation can, therefore, be performed safely after this period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several complications of renal transplantation usually do not present with graft dysfunction, there are risk factors that may contribute to allograft injury and dysfunction. These include hypertension, infection, diabetes mellitus, anemia, and urological complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is common after renal transplantation in children. During the first month following transplantation, it occurs in 80 and 60 percent of recipients of allografts from deceased and living related donors, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/52\">",
"     52",
"    </a>",
"    ]. The incidence decreases over time.",
"   </p>",
"   <p>",
"    The degree of hypertension and need for antihypertensive therapy were demonstrated by 24-hour ambulatory blood pressure monitoring in 42 children with stable renal function (average of 34 months posttransplant surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/53\">",
"     53",
"    </a>",
"    ]. The mean 24-hour systolic and diastolic blood pressures were 127 and 80 mmHg, respectively, resulting in the administration of antihypertensive medication to approximately 75 percent of patients.",
"   </p>",
"   <p>",
"    In children, posttransplant hypertension is associated with an increased risk of chronic allograft injury, decreased allograft survival, cardiovascular complications, encephalopathy, neurologic sequelae and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/54-57\">",
"     54-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of hypertension vary with the time after transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the early postoperative period, elevated blood pressure may be due to fluid overload, acute rejection, or the administration of corticosteroids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcineurin inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      After this period, the main causes of hypertension are the administration of corticosteroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcineurin inhibitors, renal artery stenosis, hypoperfused end-stage native kidneys or failed prior allografts, recurrence of primary disease, and urinary tract obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, obesity may contribute to hypertension. In a multi-center retrospective study of 234 pediatric renal transplant recipients, the prevalence of metabolic syndrome (ie, abdominal obesity, hyperglycemia, dyslipidemia, and hypertension) increased from 19 to 37 percent from the time of transplant to one-year posttransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/60\">",
"     60",
"    </a>",
"    ]. Left ventricular hypertrophy detected by echocardiogram at one-year posttransplant was more common in patients with metabolic syndrome compared with those without (55 versus 32 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of posttransplant hypertension initially begins with the administration of antihypertensive agents, even if some correctable cause is present. In our center, we tailor our pharmacologic therapy based upon the underlying cause for each individual patient. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) should be used with caution, particularly if renal artery stenosis is suspected following",
"    <span class=\"nowrap\">",
"     ultrasound/Doppler",
"    </span>",
"    examination. In such cases, angiography should be done and, if indicated, angioplasty may be successfully performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with end-stage renal disease (ESRD) are at increased risk for developing cardiovascular disease (CVD). The risk factors that lead to atherosclerosis are similar to those in the general population and include dyslipidemia and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link&amp;anchor=H5#H5\">",
"     \"Diseases associated with atherosclerosis in childhood\", section on 'Chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After transplantation, these (hypertension and dyslipidemia) and additional risk factors (eg, diabetes mellitus, hyperhomocysteinemia, and overweight) are exacerbated by the immunosuppressive drugs administered to prevent allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcineurin inhibitors are associated with hypertension and hyperhomocysteinemia",
"     </li>",
"     <li>",
"      Rapamycin is associated with dyslipidemia",
"     </li>",
"     <li>",
"      Corticosteroids are associated with hypertriglyceridemia, hypertension, increased body mass index, and diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adult kidney transplant recipients, CVD is the most common cause of mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=see_link\">",
"     \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are a permanent risk in patients receiving immunosuppressive drugs. Infections now exceed acute rejection as a cause for hospitalization during the 24 months following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/15\">",
"     15",
"    </a>",
"    ]. Infections occur most frequently soon after transplantation (first six months) when the exposure to immunosuppression is at its highest degree [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/15,63\">",
"     15,63",
"    </a>",
"    ]. Urinary tract infections (UTIs) and pulmonary infections are frequent during the early post-operative period.",
"   </p>",
"   <p>",
"    A retrospective study of 251 individual episodes of fever evaluation in 101 patients between 1995 and 2007 reported 10 percent of evaluations had positive blood cultures, 27 percent of urine cultures were positive, and in 19 percent of visits, pneumonia was diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Younger recipient age, the use of monoclonal or polyclonal antibody immunosuppressive induction therapy, and indwelling hardware are associated with an increased risk for both viral and bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Prophylactic treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    may prevent UTI and reduce the incidence of infection with Pneumocystis carinii (jirovecii) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=see_link\">",
"     \"Differential diagnosis of infection following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90900566\">",
"    <span class=\"h3\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although urinary tract infection (UTI) is a common finding posttransplant, especially in patients with a urologic etiology of ESRD, it does not appear to affect graft function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a cohort study of 87 children and young adults (mean age 15.1 &plusmn; 7.3 years) who underwent renal transplantation between 2001 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/66\">",
"     66",
"    </a>",
"    ]. All patients had received prophylactic antibiotics for at least the first year after transplantation. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UTI occurred in 15 and 32 percent of patients before and after transplantation (mean follow-up of 3.1 years).",
"     </li>",
"     <li>",
"      The median time after transplantation for posttransplant UTI was 18 months.",
"     </li>",
"     <li>",
"      The most common organisms were Klebsiella pneumoniae (30 percent) and Escherichia coli (25 percent).",
"     </li>",
"     <li>",
"      The incidence of posttransplant UTI was higher in patients with a urologic cause of ESRD (eg, posterior urethral valves) compared with those who had a medical etiology (eg, focal segmental glomerulosclerosis) (57 versus 20 percent).",
"     </li>",
"     <li>",
"      Graft function did not correlate with either a history of pretransplant or posttransplant UTI.",
"     </li>",
"     <li>",
"      Although no patient had initial vesicoureteral reflux (VUR) as documented by a cystourethrography performed one to six months after transplantation, VUR subsequently developed in five patients, two of whom had a urologic cause of ESRD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections are common and may be life-threatening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) infection may present as a primary infection in seronegative patients receiving a graft from CMV seropositive donors. It may also occur in seropositive recipients from either reactivation with the same host strain or from reinfection with the donor's strain. Infection may be asymptomatic or may present with fever, leukopenia, thrombocytopenia, pneumonitis, hepatitis, and allograft dysfunction. The incidence of significant clinical disease is higher in seronegative recipients with primary CMV infection. In addition, the disease is often more severe when the patient has been treated with antilymphocyte antibodies.",
"      <br/>",
"      <br/>",
"      Both oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/2/34848?source=see_link\">",
"       ganciclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/18/21798?source=see_link\">",
"       valganciclovir",
"      </a>",
"      have been shown to lower the risk of CMV disease and mortality. Because of the risk for the patient and for the renal allograft, prophylactic therapy is recommended for the recipient of a kidney from a seropositive donor. A discussion of the prevention and treatment of CMV infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      disease is presented in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In pediatric renal recipients, varicella infection may be responsible for severe disease including encephalitis, pneumonitis, hepatic dysfunction, and death [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/68\">",
"       68",
"      </a>",
"      ]. A varicella non-immune pediatric recipient exposed to varicella should receive postexposure prophylaxis within 72 hours of exposure. If clinical symptoms of the disease develops, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      should be given and, if administered,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil withdrawn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"       \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Immunization with the live",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      is recommended prior to transplantation in all children without varicella antibodies. This procedure reduces disease incidence and helps prevents severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. In one study, varicella infection occurred in 26 of 212 patients (12 percent) who received the vaccine but in 22 of 49 (45 percent) who had no history of varicella and were not vaccinated [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/69\">",
"       69",
"      </a>",
"      ]. Three deaths due to infection occurred among the nonvaccinated group but in none of those who were immunized. Data are insufficient to determine whether live viral vaccines should be administered to transplant recipients still on immunosuppression. Small case series have reported that varicella vaccine was administered without complications, but it was not always efficacious [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. In one small study, for example, four of six children who were non-immune responded with high antibody titers to varicella vaccination [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary Infection with Epstein-Barr virus (EBV) is common in the EBV serology negative recipient (R-) who receives an allograft from an EBV serology positive donor (D+). Reactivation of EBV in a serology positive recipient is more likely to be asymptomatic.",
"      <br/>",
"      <br/>",
"      In patients with chronic immunosuppression, posttransplant lymphoproliferative disease (PTLD) appears to be due to B cell proliferation induced by infection with Epstein-Barr virus (EBV). The risk of PTLD is highest in the R- recipient who received an allograft from a D+ donor [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/73\">",
"       73",
"      </a>",
"      ]. Since more infants and young children are R-, more of these patients will develop PTLD. However, once infected with EBV, adolescents are at significantly higher risk to progress to PTLD and have poorer outcomes compared to younger recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/74\">",
"       74",
"      </a>",
"      ]. Reductions in immunosuppression are recommended in this setting and some children will require treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of Herpes simplex virus either as primary infection or reactivation depends on the degree of immunosuppression and time after transplant. Both",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/35/3638?source=see_link\">",
"       valacyclovir",
"      </a>",
"      are effective agents in the treatment of HSV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"       \"Treatment of genital herpes simplex virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      BK (polyomavirus) viral infection is an important cause of allograft dysfunction in pediatric renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/75-78\">",
"       75-78",
"      </a>",
"      ]. An analysis of the NAPRTCS registry demonstrated a 5 percent incidence of BK virus-induced nephropathy in renal recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/79\">",
"       79",
"      </a>",
"      ]. Seronegative patients are at the greatest risk for developing BK virus-induced nephropathy.",
"      <br/>",
"      <br/>",
"      In a case series of 20 pediatric renal recipients with BK viremia, children with BK virus-induced nephropathy presented later, and had higher viral loads and serum creatinine levels compared to those who were viremic without nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/80\">",
"       80",
"      </a>",
"      ]. Children with BK virus-induced nephropathy who remained viremic (ie, persistent + polymerase chain reaction [PCR]) despite reduction of immunosuppression and antiviral treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/34/14886?source=see_link\">",
"       cidofovir",
"      </a>",
"      were at greater risk for loss of renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=see_link\">",
"       \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A screening and preemptive strategy similar to the one used in adult renal recipients appears to be effective in preventing BK nephropathy in pediatric patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/81\">",
"       81",
"      </a>",
"      ]. This approach involves monitoring for viremia by PCR, and reducing immunosuppression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administration of antiviral agents after the detection of very early systemic infection (+PCR). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link\">",
"       \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Warts due to human papillomaviruses (HPV) are common in pediatric renal recipients. To date, there have been no randomized controlled studies regarding the use of HPV vaccines in these patients, and so it remains uncertain whether or not this vaccine is immunogenic in the posttransplant immunosuppressed patient [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/82\">",
"       82",
"      </a>",
"      ]. Until such data are available, HPV vaccine should be administered according to current guidelines to female candidates (ages 9 to 26 years) prior to transplant candidates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy in renal transplant recipients is associated with an increased risk of malignancy. Data from the NAPRTCS registry show an overall malignancy incidence of 2.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/3\">",
"     3",
"    </a>",
"    ]. Of the 255 confirmed malignancies, 215 were lymphoproliferative disease (LPD) and 40 are non-LPD. The median time from transplant to malignancy was 12.7 and 17 months for LPD and non-LPD, respectively. Since the late 1980s, the risk of LPD has increased. The risk markedly increased among children receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (11.5 versus 1.1 percent for those administered",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). A greater frequency of malignancy also occurred in white children and recipients of deceased donor transplants.",
"   </p>",
"   <p>",
"    In a French retrospective study of 1326 children following solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/83\">",
"     83",
"    </a>",
"    ], there was a 6 percent incidence of malignancy following transplantation, and LPD was diagnosed in 80 percent of the tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transitional cell carcinoma and gastric adenocarcinoma have been reported in patients who have undergone bladder augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. It remains unknown if immunosuppression increases the risk of malignancy in patients with either enterocystoplasty or gastrocystoplasty. Routine ultrasound and endoscopic surveillance is recommended beginning 10 years after the bladder augmentation procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of posttransplant diabetes mellitus ranges from 1 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. Risk factors include exposure to calcineurin inhibitors (particularly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) and corticosteroid therapy, and African-American ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is extremely common among pediatric allograft recipients. In a retrospective cohort study of 167 such children, the prevalence of anemia was approximately 60 to 80 percent at 6 to 60 months posttransplantation, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/89\">",
"     89",
"    </a>",
"    ]. In this series of patients, development of anemia was related to multiple factors, including iron deficiency, immunosuppressive therapy, bone disease, and decreased renal function. Parvovirus b19 infection has also been reported as a cause of severe anemia in pediatric renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Surgical sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical sequelae include both urologic and vascular complication and are a major cause of graft loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular complications include vascular (arterial or venous) stricture and thrombosis. The risk of vascular complications is higher in younger patients (less than six years of age), which may lead to graft loss [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously mentioned, common early complications following renal transplantation included urinary leak and urinary obstruction. These sequelae may cause delayed graft function. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Urologic complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other urological complications that present later include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ureteral obstruction due to stenosis may occur at the level of the anastomosis or at the pyeloureteral junction when the kidney has been turned by 180 degrees to facilitate vascular anastomosis. In one case series of 526 renal transplants from a single tertiary center, ureteral obstruction occurred in 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/92\">",
"       92",
"      </a>",
"      ]. Posterior ureteral valves appeared to be a risk factor for ureteral obstruction, perhaps due to pretransplant bladder ischemia, thickness, and collagen remodeling. About one-half of patients presented within 100 days after renal transplantation.",
"     </li>",
"     <li>",
"      Nephrolithiasis occurs in 2 to 3 percent of cases.",
"     </li>",
"     <li>",
"      Vesicoureteral reflux (VUR). One case series reported an incidence of VUR of 58 percent of pediatric renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bladder dysfunction is common among patients with posterior urethral valves and meningomyeloceles. It may cause chronic obstruction and be associated with recurrent urinary tract infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=see_link\">",
"       \"Clinical presentation and diagnosis of posterior urethral valves\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=see_link\">",
"       \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective study of 202 renal transplants in 193 children performed in a single French center from 1989 to 2007, the risk of urological and vascular complications was 22 and 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/40/22154/abstract/91\">",
"     91",
"    </a>",
"    ]. Urological complications included VUR (12 percent), ureteral stricture (5 percent), anastomotic leak (2 percent), and ureteral necrosis (1 percent). Vascular complications included arterial stricture (7 percent), arterial thrombosis (2 percent), and venous thrombosis (1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in immunosuppressive therapy and posttransplant management have led to improvements in both graft and patient survival in pediatric renal transplant recipients. However, long-term success has been limited by complications due to immunosuppression, rejection, and recurrent disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many complications of renal transplantation present as graft dysfunction. The causes of graft dysfunction vary with the time after transplantation in children similar to that of adult renal recipients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Graft dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of delayed graft function that occur after transplantation include postischemic acute kidney injury, vascular thrombosis of the renal artery or vein, urinary leak or obstruction, and hyperacute rejection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Delayed graft function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Causes of graft dysfunction between 1 and 12 weeks posttransplantation include calcineurin inhibitor nephrotoxicity (CIN), acute rejection, urinary obstruction, infection, hypovolemia, and recurrent disease.",
"     </li>",
"     <li>",
"      Causes of graft dysfunction that develop acutely more than three months after transplantation include acute rejection, CIN, urinary obstruction, hypovolemia, and recurrent and de novo renal disease.",
"     </li>",
"     <li>",
"      Causes of graft dysfunction that slowly develops over years includes chronic allograft injury, CIN, hypertensive nephrosclerosis, viral infections, and recurrent or de novo renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute rejection is suggested by an acute elevation in the serum creatinine (Cr) level and confirmed by histologic findings of acute antibody-mediated and cellular rejection. Serum Cr should be routinely monitored for early detection of acute rejection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute rejection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although chronic allograft injury is the most common cause of graft loss after the first year following transplantation, its underlying cause remains unknown. The diagnosis is suggested by a slowly rising serum Cr, increasing proteinuria, and worsening hypertension. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic allograft injury'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"       \"Chronic renal allograft nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CIN may occur acutely and is largely reversible after dose reduction, or as chronic progressive renal disease, which is usually irreversible. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Calcineurin inhibitor toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, recurrence of primary disease is responsible for graft failure in 5 to 15 percent of cases. Primary pediatric renal diseases with a high recurrence rate in the transplanted kidney include focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis types I and II, genetic forms of hemolytic uremic syndrome, and primary hyperoxaluria. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recurrence of primary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other complications that occur in pediatric renal recipients include hypertension, cardiovascular disease, infection, malignancy, diabetes mellitus, anemia, and surgical sequelae (eg, urological and vascular complications). These may contribute to allograft injury and dysfunction. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/2\">",
"      McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2008. Available at: https://web.emmes.com/study/ped/announce.htm (Accessed on November 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/4\">",
"      Locke JE, Segev DL, Warren DS, et al. Outcomes of kidneys from donors after cardiac death: implications for allocation and preservation. Am J Transplant 2007; 7:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/5\">",
"      McDonald RA, Smith JM, Stablein D, Harmon WE. Pretransplant peritoneal dialysis and graft thrombosis following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant 2003; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/6\">",
"      Smith JM, Stablein D, Singh A, et al. Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant 2006; 6:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/7\">",
"      Kranz B, Vester U, Nadalin S, et al. Outcome after kidney transplantation in children with thrombotic risk factors. Pediatr Transplant 2006; 10:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/8\">",
"      Kim MS, Stablein D, Harmon WE. Renal transplantation in children with congenital nephrotic syndrome: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998; 2:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/9\">",
"      Salvatierra O Jr, Millan M, Concepcion W. Pediatric renal transplantation with considerations for successful outcomes. Semin Pediatr Surg 2006; 15:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/10\">",
"      Routh JC, Yu RN, Kozinn SI, et al. Urological complications and vesicoureteral reflux following pediatric kidney transplantation. J Urol 2013; 189:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/11\">",
"      Tavakoli A, Surange RS, Pearson RC, et al. Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J Urol 2007; 177:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/12\">",
"      Dharnidharka VR, Araya CE, Wadsworth CS, et al. Assessing the value of ureteral stent placement in pediatric kidney transplant recipients. Transplantation 2008; 85:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/13\">",
"      Salmela KT, von Willebrand EO, Kyll&ouml;nen LE, et al. Acute vascular rejection in renal transplantation--diagnosis and outcome. Transplantation 1992; 54:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/14\">",
"      Grandtnerov&aacute; B, M&auml;ckov&aacute; N, Hovoricov&aacute; B, Jahnov&aacute; E. Hyperacute rejection of living related kidney grafts caused by endothelial cell-specific antibodies: case reports. Transplant Proc 2008; 40:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/15\">",
"      Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/16\">",
"      Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/17\">",
"      Benfield MR, Herrin J, Feld L, et al. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/18\">",
"      Birk PE, Blydt-Hansen TD, Dart AB, et al. Low incidence of adverse events in outpatient pediatric renal allograft biopsies. Pediatr Transplant 2007; 11:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/19\">",
"      Birk PE, Rush DN. Protocol biopsies should be standard of care for pediatric renal allograft recipients! Pediatr Transplant 2006; 10:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/20\">",
"      Shapiro R, Starzl TE. Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients. Pediatr Transplant 2006; 10:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/21\">",
"      Guyot C, Nguyen JM, Cochat P, et al. Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatr Nephrol 1996; 10:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/22\">",
"      Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/23\">",
"      Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/24\">",
"      Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/25\">",
"      Lin CC, King KL, Chao YW, et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/26\">",
"      Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/27\">",
"      Feinstein S, Keich R, Becker-Cohen R, et al. Is noncompliance among adolescent renal transplant recipients inevitable? Pediatrics 2005; 115:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/28\">",
"      Rianthavorn P, Ettenger RB. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint. Pediatr Transplant 2005; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/29\">",
"      Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation 2009; 87:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/30\">",
"      Ettenger RB, Rosenthal JT, Marik JL, et al. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol 1991; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/31\">",
"      Meyers KE, Thomson PD, Weiland H. Noncompliance in children and adolescents after renal transplantation. Transplantation 1996; 62:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/32\">",
"      Schweizer RT, Rovelli M, Palmeri D, et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/33\">",
"      Chisholm-Burns MA, Spivey CA, Rehfeld R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant 2009; 9:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/34\">",
"      Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/35\">",
"      Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation 2009; 88:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/36\">",
"      Beck DE, Fennell RS, Yost RL, et al. Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants. J Pediatr 1980; 96:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/37\">",
"      Cameron JS. Recurrent primary disease and de novo nephritis following renal transplantation. Pediatr Nephrol 1991; 5:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/38\">",
"      Cochat P, Fargue S, Mestrallet G, et al. Disease recurrence in paediatric renal transplantation. Pediatr Nephrol 2009; 24:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/39\">",
"      Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2:S258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/40\">",
"      Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 2007; 22:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/41\">",
"      Senggutuvan P, Cameron JS, Hartley RB, et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/42\">",
"      Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/43\">",
"      Habib R, Hebert D, Gagnadoux MF, Broyer M. Transplantation in idiopathic nephrosis. Transplant Proc 1982; 14:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/44\">",
"      Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/45\">",
"      Weber S, T&ouml;nshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005; 80:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/46\">",
"      Habib R, Antignac C, Hinglais N, et al. Glomerular lesions in the transplanted kidney in children. Am J Kidney Dis 1987; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/47\">",
"      Braun MC, Stablein DM, Hamiwka LA, et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/48\">",
"      Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/49\">",
"      Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/50\">",
"      Bobrowski AE, Langman CB. The primary hyperoxalurias. Semin Nephrol 2008; 28:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/51\">",
"      Penn I. Renal transplantation for Wilms tumor: report of 20 cases. J Urol 1979; 122:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/52\">",
"      Broyer M, Guest G, Gagnadoux MF, Beurton D. Hypertension following renal transplantation in children. Pediatr Nephrol 1987; 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/53\">",
"      Sorof JM, Poffenbarger T, Portman R. Abnormal 24-hour blood pressure patterns in children after renal transplantation. Am J Kidney Dis 2000; 35:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/54\">",
"      Baluarte HJ, Gruskin AB, Ingelfinger JR, et al. Analysis of hypertension in children post renal transplantation--a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 1994; 8:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/55\">",
"      Ingelfinger JA, Brewer ED. Pediatric post-transplant hypertension: a review of current standards of care. Child Nephrol Urol 1992; 12:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/56\">",
"      Malekzadeh MH, Brennan LP, Payne VC Jr, Fine RN. Hypertension after renal transplantation in children. J Pediatr 1975; 86:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/57\">",
"      Sorof JM, Sullivan EK, Tejani A, Portman RJ. Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999; 10:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/58\">",
"      Curtis JJ. Hypertension after renal transplantation: cyclosporine increases the diagnostic and therapeutic considerations. Am J Kidney Dis 1989; 13:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/59\">",
"      Luke RG. Pathophysiology and treatment of posttransplant hypertension. J Am Soc Nephrol 1991; 2:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/60\">",
"      Wilson AC, Greenbaum LA, Barletta GM, et al. High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant 2010; 14:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/61\">",
"      McMullin ND, Reidy JF, Koffman CG, et al. The management of renal transplant artery stenosis in children by percutaneous transluminal angioplasty. Transplantation 1992; 53:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/62\">",
"      Becker-Cohen R, Nir A, Rinat C, et al. Risk factors for cardiovascular disease in children and young adults after renal transplantation. Clin J Am Soc Nephrol 2006; 1:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/63\">",
"      Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007; 7:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/64\">",
"      Yin S, Powell EC, Trainor JL. Serious bacterial infections in febrile outpatient pediatric kidney transplant recipients. Pediatr Infect Dis J 2011; 30:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/65\">",
"      Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990; 89:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/66\">",
"      Silva A, Rodig N, Passerotti CP, et al. Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol 2010; 184:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/67\">",
"      Esezobor CI, Nourse P, Gajjar P. Urinary tract infection following kidney transplantation: frequency, risk factors and graft function. Pediatr Nephrol 2012; 27:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/68\">",
"      Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/69\">",
"      Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/70\">",
"      Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/71\">",
"      Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr 2008; 4:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/72\">",
"      Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005; 9:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/73\">",
"      McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/74\">",
"      Smith JM, Corey L, Healey PJ, et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/75\">",
"      Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/76\">",
"      Herman J, Van Ranst M, Snoeck R, et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 2004; 8:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/77\">",
"      Haysom L, Rosenberg AR, Kainer G, et al. BK viral infection in an Australian pediatric renal transplant population. Pediatr Transplant 2004; 8:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/78\">",
"      M&uuml;ller A, Beck B, Theilemann K, et al. Detection of polyomavirus BK and JC in children with kidney diseases and renal transplant recipients. Pediatr Infect Dis J 2005; 24:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/79\">",
"      Smith JM, Dharnidharka VR, Talley L, et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/80\">",
"      Hymes LC, Warshaw BL. Polyomavirus (BK) in pediatric renal transplants: evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/81\">",
"      Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/82\">",
"      Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/83\">",
"      Debray D, Baudouin V, Lacaille F, et al. De novo malignancy after solid organ transplantation in children. Transplant Proc 2009; 41:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/84\">",
"      Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/85\">",
"      Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol 2007; 178:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/86\">",
"      Robert JJ, Tete MJ, Crosnier H, Broyer M. [Sugar diabetes after renal transplantation in children]. Ann Pediatr (Paris) 1993; 40:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/87\">",
"      Al-Uzri A, Stablein DM, A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/88\">",
"      Burroughs TE, Swindle JP, Salvalaggio PR, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation 2009; 88:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/89\">",
"      Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/90\">",
"      Pinto V, Grandy J, Zambrano P, et al. Severe anemia from parvovirus b19 infection in pediatric renal transplant recipients: two case reports. Transplant Proc 2008; 40:3261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/91\">",
"      Irtan S, Maisin A, Baudouin V, et al. Renal transplantation in children: critical analysis of age related surgical complications. Pediatr Transplant 2010; 14:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/92\">",
"      Smith KM, Windsperger A, Alanee S, et al. Risk factors and treatment success for ureteral obstruction after pediatric renal transplantation. J Urol 2010; 183:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/40/22154/abstract/93\">",
"      Ranchin B, Chapuis F, Dawhara M, et al. Vesicoureteral reflux after kidney transplantation in children. Nephrol Dial Transplant 2000; 15:1852.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6143 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22154=[""].join("\n");
var outline_f21_40_22154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GRAFT DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Delayed graft function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Vascular thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Urologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperacute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic allograft injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calcineurin inhibitor toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonadherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECURRENCE OF PRIMARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90900566\">",
"      - Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Surgical sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=related_link\">",
"      Differential diagnosis of infection following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=related_link\">",
"      General principles of kidney transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39367?source=related_link\">",
"      IgA nephropathy: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=related_link\">",
"      Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=related_link\">",
"      Outcomes of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=related_link\">",
"      Risk factors for cardiovascular disease in the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=related_link\">",
"      Screening for inherited thrombophilia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12053?source=related_link\">",
"      TTP-HUS: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=related_link\">",
"      Urinary tract complications of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_40_22155="Diagnosis of X linked LPD";
var content_f21_40_22155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for X-Linked lymphoproliferative disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definitive diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male patient with lymphoma/Hodgkin disease, fatal EBV infection, immunodeficiency, aplastic anemia, or lymphohistiocytic disorder and who has a mutation in SH2D1 A/SAP/DSHP.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Probable diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male patient experiencing death, lymphoma/Hodgkin disease, immunodeficiency, aplastic anemia, or lymphohistiocytic disorder following acute EBV infection and having maternal cousins, uncles, or nephews with a history of similar diagnoses following acute EBV infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male patient experiencing death, lymphoma/Hodgkin disease, immunodeficiency, aplastic anemia, or lymphohistiocytic disorder following acute EBV infection.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.",
"    </div>",
"    <div class=\"reference\">",
"     From Conley, ME, Notarangelo, LD, Etzioni, A. Clin Immunol 1999; 93:190.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22155=[""].join("\n");
var outline_f21_40_22155=null;
var title_f21_40_22156="Karyotype risk AML";
var content_f21_40_22156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Standardized reporting for correlation of cytogenetic and molecular genetic data in acute myeloid leukemia (AML) in adults with clinical data*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Genetic group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Subsets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Favorable",
"      </td>",
"      <td>",
"       t(8;21)(q22;q22); RUNX1-RUNX1T1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutated NPM1 without FLT3-ITD (normal karyotype)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutated CEBPA (normal karyotype)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Intermediate-I&bull;",
"      </td>",
"      <td>",
"       Mutated NPM1 and FLT3-ITD (normal karyotype)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wild type NPM1 and FLT3-ITD (normal karyotype)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wild type NPM1 without FLT3-ITD (normal karyotype)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Intermediate-II",
"      </td>",
"      <td>",
"       t(9;11)(p22;q23); MLLT3-MLL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytogenetic abnormalities not classified as favorable or adverse&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Adverse",
"      </td>",
"      <td>",
"       inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(6;9)(p23;q34); DEK-NUP214",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(v;11)(v;q23); MLL rearranged",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -5 or del(5q); -7; abnl(17p); complex karyotype&loz;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Frequencies, response rates and outcome measures should be reported by genetic group, and, if sufficient numbers are available, by specific subsets indicated; excluding cases of acute promyelocytic leukemia.",
"     <br>",
"      &bull; Includes all AMLs with normal karyotype except for those included in the favorable subgroup; most of these cases are associated with poor prognosis, but they should be reported separately because of the potential different response to treatment.",
"      <br>",
"       &Delta; For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance.",
"       <br>",
"        &loz; Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, ie, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3)/t(3;3); indicate how many complex karyotype cases have involvement of chromosome arms 5q, 7q, and 17p.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Dohner, H, Estey, EH, Amadori, S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel on behalf of the European LeukemiaNet. Blood 2009. Copyright &copy; American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22156=[""].join("\n");
var outline_f21_40_22156=null;
var title_f21_40_22157="RT postmastectomy local recur";
var content_f21_40_22157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of treatment for isolated postmastectomy chest wall recurrence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Author; year",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       n",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Median follow-up, months",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Local control, percent",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       FFDM",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       OS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       5 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       10 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       5 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       10 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aberizk, WJ; 1986",
"      </td>",
"      <td>",
"       90",
"      </td>",
"      <td>",
"       81",
"      </td>",
"      <td>",
"       35 (10-yr)",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       26",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Deutsch, M; 1986",
"      </td>",
"      <td>",
"       107",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       45 (5-yr)",
"      </td>",
"      <td>",
"       35 (RFS)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mendenhall, N; 1988",
"      </td>",
"      <td>",
"       47",
"      </td>",
"      <td>",
"       24 (min)",
"      </td>",
"      <td>",
"       61 (10-yr)",
"      </td>",
"      <td>",
"       41",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       34",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Halverson, K; 1990",
"      </td>",
"      <td>",
"       224",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       57 (5-yr)",
"      </td>",
"      <td>",
"       25 (RFS)",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       26",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Schwaibold, F; 1991",
"      </td>",
"      <td>",
"       128",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       43 (5-yr)",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       49",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Borner, M; 1994",
"      </td>",
"      <td rowspan=\"2\">",
"       167",
"      </td>",
"      <td rowspan=\"2\">",
"       76",
"      </td>",
"      <td>",
"       RT alone: 65 (5-yr)",
"      </td>",
"      <td>",
"       36",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       76",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RT + Tam: 88 (5-yr)",
"      </td>",
"      <td>",
"       59",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hsi, R; 1998",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       86 (10-yr)",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       42 (RFS)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       72",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       van Tienhoven, G; 1999",
"      </td>",
"      <td>",
"       67",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       62 (5-yr)",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       58",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ballo, M; 1999",
"      </td>",
"      <td>",
"       148",
"      </td>",
"      <td>",
"       78",
"      </td>",
"      <td>",
"       <p>",
"        68 (5-yr)",
"       </p>",
"       <p>",
"        55 (10-yr)",
"       </p>",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Haylock, B; 2000",
"      </td>",
"      <td rowspan=\"2\">",
"       120",
"      </td>",
"      <td rowspan=\"2\">",
"       24",
"      </td>",
"      <td>",
"       RT alone: 66 (10-yr)",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       45",
"      </td>",
"      <td>",
"       74",
"      </td>",
"      <td>",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RT + chemo: 58 (10-yr)",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       49",
"      </td>",
"      <td>",
"       82",
"      </td>",
"      <td>",
"       62",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Haffty, B; 2004",
"      </td>",
"      <td>",
"       113",
"      </td>",
"      <td>",
"       121",
"      </td>",
"      <td>",
"       79 (10-yr)",
"      </td>",
"      <td>",
"       49",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       28",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kuo, S; 2008",
"      </td>",
"      <td>",
"       115",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       83",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       79",
"      </td>",
"      <td>",
"       59",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FFDM: freedom from distant metastases; OS: overall survival; RT: radiation therapy; Tam: tamoxifen; chemo: systemic chemotherapy; min: minimum; RFS: relapse-free survival; NR: not reported.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22157=[""].join("\n");
var outline_f21_40_22157=null;
var title_f21_40_22158="Right atrial pressure tracings in tricuspid regurgitation";
var content_f21_40_22158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Right atrial pressure tracing in tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous electrocardiographic and right atrial pressure tracings from a patient with tricuspid regurgitation. Right atrial pressure tracing shows prominent 'v' waves, caused as blood is regurgitated into the atrium during ventricular systole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22158=[""].join("\n");
var outline_f21_40_22158=null;
var title_f21_40_22159="Palpation sacroiliac joint";
var content_f21_40_22159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the sacroiliac joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sacroiliac joint is palpated for local tenderness in patients in whom an intrinsic hip condition is unlikely but who complain of posterior hip pain. The sacroiliac joint is located 1 inch medial and 1 inch inferior to the posterior superior iliac spine. The patient is placed in the prone position. Firm to hard pressure is placed directly over the upper portion of the sacroiliac joint. Sacroiliac strain and sacroiliitis cause focal tenderness, approximately the size of a half dollar. Diffuse tenderness extending over a wide area is seen with severe paraspinal muscle spasm. Local tenderness that does not conform to the typical area of the joint should suggest involvement of the adjacent bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_40_22159=[""].join("\n");
var outline_f21_40_22159=null;
  